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SUMMARY 
Stroke is a growing cause of morbidity and a significant cause of mortality in the 
United States. Currently, no therapies can promote recovery of neuronal networks 
lost to cerebral infarction. Tissue engineering strategies such as cellular therapy 
may be able to enhance functional regeneration of brain tissue. Neural progenitor 
cells (NPCs) are at the forefront of preclinical studies for regenerative stroke 
therapies. NPCs can differentiate into and replace neurons and promote 
endogenous recovery mechanisms. The stroke core region is the ideal location for 
replacement of neural tissue since it is in situ, and following degradation, develops 
into a potential space for targeting injections. However, the compromised cortical 
perfusion and degradation of the extracellular matrix following ischemia create an 
inhospitable environment resistant to cellular therapy. Overcoming these 
limitations are critical for clinical translation. In our studies, we test whether 
encapsulation of NPCs in a chondroitin-4-sulfate-A (CS-A) hydrogel enhances 
their ability to repair the injured brain following stroke in mice. We show that CS-A 
encapsulated NPCs improve vascular regeneration at multiple levels to increase 
cerebral blood flow. These outcomes are likely mediated by enhanced paracrine 
signaling effects and regenerative immunomodulation. Further research and 
additional strategies are necessary to overcome the shortcomings of CS-A 
encapsulated NPC treatment.  In summary, extending the therapeutic potential of 
NPCs using angiogenic biomaterials such as CS-A may be a viable solution to 
overcoming limitations for regenerative cellular therapy in ischemic stroke. 
 1
INTRODUCTION 
Ischemic stroke is one of the leading causes of mortality and morbidity worldwide, 
and the 5th leading cause of death in the US [1]. Nearly 800,00 people encounter 
new or recurrent stroke yearly in the US alone, and few successful treatments have 
been developed to treat this disease. Importantly, stroke is the leading cause of 
long-term disability, and there are millions of people with brain damage [2]. Current 
therapy guidelines involve reperfusion either by treatment with tissue plasminogen 
activator or by surgery, and in most cases, must be carried out within 6-24 hours 
after stroke onset.  At the present time, there are no therapies that promote tissue 
recovery after this brief therapeutic window following cerebral infarction.  
Cellular therapies made available using stem cell techniques hold promise for 
improving functional recovery after ischemia via mechanisms involving both 
trophic support and cell replacement [3-7]. Induced pluripotent stem cells (iPSCs) 
can be reprogrammed from autologous host cells to minimize immunogenicity and 
are at the forefront of pre-clinical studies for regenerative medicine [5, 8-13]. 
Transplanted iPSC derived neural progenitor cells (iPSC-NPCs) can differentiate 
into functional neurons that can integrate and replace host circuitry lost to stroke 
[14-20]. iPSC-NPCs also promote endogenous recovery mechanisms such as 
enhanced vascularization and host neuronal plasticity, immunosuppression, and 
recruitment endogenous progenitor cells [4, 6, 7, 21-25]. Released proteins such 
as growth factors and interleukins play an integral role in mediating these 
regenerative properties [4, 22, 26-28]. The current bottlenecks for iPSC-NPC 
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treatments include graft survival and retention following transplantation amidst the 
toxic stroke core, limited efficacy of improving homeostatic compensatory repair 
mechanisms, and restricted integration of differentiated cells into existing neural 
networks [10-12].  
However, the specific pathophysiology of ischemic stroke makes infarcted 
brain tissue especially resistant to cellular therapy. Immediately following 
cessation of blood supply, cellular energy homeostasis is disrupted, and cell death 
develops within minutes [29]. Furthermore, the blood brain barrier is disrupted, 
leading to increased permeability of reactive oxygen species and inflammatory 
mediators, which can exacerbate the initial damage [30]. Following loss of blood 
flow, normal ionic gradients important for cellular membrane potential and neuronal 
signaling dilapidate and result in the release of toxic amounts of glutamate, which 
can reside in the tissue for days. Intracellular and extracellular proteases are 
activated which results both cellular damage and degradation of the extracellular 
matrix. Following this initial wave of cell death during the acute phase of stroke, 
inflammatory cells such as microglia/macrophages and monocytes infiltrate the 
hypoxic tissue [29]. Microglia/macrophages in the stroke region tend to exhibit a 
pro-inflammatory phenotype (M1/classically activated), which further antagonizes 
regenerative efforts. Days to weeks after focal brain ischemia, astrocytes 
congregate to create an interface between the core infarct region and the viable 
parenchyma to limit the spread of toxic inflammation. However, this astrocytic scar 
is thought to be inhibitory to axonal growth of both newly formed endogenous 
neurons and transplanted cells [29]. The adult brain’s innate ability to recreate 
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damage neural tissue is extremely limited. After an ischemic insult, neural stem 
cells in the subventricular zone are recruited to the peri-infarct region where they 
can become newborn neurons. Unfortunately, the scale at which this occurs in 
humans without intervention is insufficient to generate meaningful recovery. 
Previous studies have attempted to overcome or bypass some of these difficulties 
by either increasing the resiliency and efficacy of the transplanted cells (for 
example, by hypoxic preconditioning [23, 24, 31] or genetic manipulation [32]), or 
by transplanting in the peri-infarct region where the microenvironment is less 
hostile. These efforts have proven useful but ultimately insufficient for clinical 
translation. Furthermore, directing injections to the peri-infarct region requires 
invasive placement in sensitive brain tissue, which can be damaged simply by 
delivery approach [33-35].  
An alternative strategy is to create a microenvironment in the stroke core 
favorable for transplantation and regeneration via hydrogel encapsulation [3, 11, 
12, 36-39]. Hydrogels are biocompatible carrier materials that can be used to 
promote survival, differentiation, trophic potency, and functional integration of 
transplanted cells [27, 37, 40-42]. Their ability to emulate the biophysical properties 
of soft neural tissue makes them ideal for engraftment into brain injuries [27, 43-
48]. Previous studies have utilized hydrogels composed of extracellular matrix 
(ECM) such as hyaluronan (HA) to enhance transplant cell viability and direct 
differentiation of stem cells with varying success. Hyaluronan (HA) is a well-studied 
brain resident extracellular matrix (ECM) component that has previously been used 
as a hydrogel carrier for cellular therapy in stroke studies [33, 37, 41, 45]. HA can 
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improve cell survival after transplant, promote angiogenesis and anti-inflammatory 
signaling, and encourage neuronal differentiation of stem cells [27, 37, 41, 45]. 
Recently, a HA-based hydrogel was demonstrated to encourage vascular repair 
and neuronal migration to the stroke core in mice[49]. However, low molecular 
weight HA is pro-inflammatory, and transplanting HA into the degradatory stroke 
core would carry an unnecessary risk of exacerbating inflammation [37, 41, 50].  
Unlike HA, chondroitin-4-sulfate (chondroitin sulfate-A/CS-A) possesses 
greater structural and functional elements to modulate trophic factor enrichment 
and promote autocrine/paracrine signaling [51, 52]. Endogenously, CS-A is an 
integral ECM constituent of the neural stem cell niche [47, 51-54]. ECM binding is 
a critical step of growth factor-mediated tissue repair [55]. Regenerative factors 
such as basic fibroblast growth factor (bFGF/FGF2) and brain-derived 
neurotrophic factor (BDNF), and the immunomodulatory protein interleukin 10 (IL-
10) have high affinities for CS-A [53]. Our collaborators have recently shown that 
CS-A can improve growth factor and transplanted cell retention in a rat traumatic 
brain injury model, however, they are wholly unexplored as transplant mediums for 
the treatment of stroke [39, 53]. We hypothesize that these polymers can be used 
to create a depot in the stroke core for the growth factors necessary to synergize 
with and enable NPC-mediated tissue regeneration. 
In the present study, we investigated the ability of CS-A to facilitate 
transplanted NPC survival, retention, and differentiation, the effects of CS-A 
encapsulation of NPCs on regenerative processes in the brain, and the extent to 
which CS-A could facilitate functional recovery of blood flow and behavioral 
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outcomes after ischemic stroke in mice.  
  
 6
SPECIFIC AIMS AND HYPOTHESES 
 The overarching goal of this project is to improve the therapeutic value of 
neural progenitor cells for the treatment of ischemic stroke. Transplantation of 
NPCs can help to repair damaged neural networks and enhance endogenous 
regeneration after stroke. However, several critical issues remain to be improved 
for the development of more effective and efficient stem cell treatment. Many 
transplanted cells die in the harsh stroke core and fail to differentiate into neurons 
or facilitate paracrine effects. We propose to encapsulate induced pluripotent stem 
cell derived NPCs in a neuro-regenerative and angiogenic chondroitin-4-sulfate-A 
hydrogel and hypothesize that this beneficial extracellular matrix scaffolding will 
provide an enriched environment for enhanced retention and trophic potential of 
transplanted NPCs. This central hypothesis was tested with the aims described 
below.  
2.1  Aim 1: Determine the effects of CS-A on NPC survival and differentiation. 
Transplanted NPCs may replace neurons lost to the ischemic brain damage. We 
hypothesize that CS-A encapsulation of NPCs will support neuronal differentiation 
in vitro and after transplantation into the ischemic brain. I hypothesize that CS-A 
encapsulation will enhance transplant cell survival and retention even in the 
ischemic core region. NPCs encapsulated CS-A will be transplanted into the 
ischemic core 7 days after cerebral ischemia targeting the right sensorimotor 
cortex in adult mice. Cell survival will be inspected after transplantation using 
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining, 
and cell death/survival protein expression will be measured using Western blotting 
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and immunohistochemical (IHC) staining of brain sections. Cellular retention will 
be evaluated using IHC and tracking of DiIC18(7); 1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindotricarbocyanine iodide (DiR) labelled cells. The effect of CS-A 
encapsulation on iPSC-NPC differentiation will be interrogated at the molecular 
and cellular levels using Western blotting and immunohistochemistry.  
2.2  Aim 2: Determine the effects of treatment with CS-A encapsulated NPC 
on regeneration in the ischemic brain. 
Following successful engraftment, NPCs can improve endogenous angiogenesis, 
neurogenesis, and lessen inflammation [56-58]. Regenerative factor recruitment 
and retention are critical for this trophic support. We hypothesized that CS-A can 
augment NPC-mediated neuronal and vascular regeneration, and promote a pro-
regenerative immune phenotype. Stroke mice will be treated with BrdU daily after 
treatment to label newly formed cells. The regenerative factor enriching effects of 
CS-A will be investigated using IHC and Western blotting. Microglia/macrophage 
polarization and astrocyte reactivity will be compared by IHC, Western blotting, 
and protein array assays. The potential specific effects of the CS-A hydrogel on 
stroke core microglia and brain endothelial will also be tested using in vitro 
methods.  We will also employ a novel microfluidic hydrogel migration preference 
assay to test the effects of CS-A on recruitment of endothelial cells.  
2.3  Aim 3: Determine the effects of treatment with CS-A encapsulated NPCs 
on local blood flow restoration and functional recovery after ischemic 
stroke. 
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Functional recovery is the ultimate goal for stroke treatment. Pial collateral artery 
recruitment and blood flow enhancement are essential to recovery. Mice with 
sensorimotor cortex stroke suffer from whisker and forearm sensorimotor deficits 
and gradually develop depression-like behaviors. I hypothesize that 
transplantation of CS-A encapsulated NPCs will promote additional collateral 
recruitment and regional blood flow recovery and will improve behavioral deficits 
following stroke. Arterial characteristics will be analyzed using fluorescent imaging 
of whole brains isolated from αSMA-GFP mice, and blood flow recovery will be 
measured using laser doppler scanning. Sensorimotor recovery will be evaluated 
using adhesive removal, cylinder, rotarod, volitional isometric pull strength, and 
corner tests. Recovery from post-stroke depressive-like behaviors will be 
evaluated by tail suspension, forced swim, open field, sucrose preference, and 
home cage monitoring tests.  
 The research proposed in these specific aims will provide insight into the 
potential benefits of CS-A encapsulation of NPCs for the treatment of ischemic 
stroke.   
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LITERATURE REVIEW 
3.1 Stroke Epidemiological Trends 
Stroke is one of the leading causes of death or long-term disability worldwide. 
According to the American Heart Association, stroke became the fifth leading 
cause of death in the United States in 2013 [2]. Nearly 1 in 20 people in the United 
States die due to stroke. Fortunately, population trends for stroke are improving. 
Over the last decade, the relative rate of death from stroke has decreased by 
nearly a third, and the number of stroke deaths fell by 18.2%. Overall, stroke 
mortality has declined across sex, race, and age. Stroke death rates have 
decreased among people aged ≥ 65 years. Many of these improvements are 
attributed to improved preventative, perioperative, and management guidelines, 
resulting in both reduced stroke incidence and lower stroke fatality rates [2, 59-61]. 
However, despite these promising epidemiological trends, nearly 800,00 people 
encounter new or recurrent stroke yearly in the US alone, and few successful 
treatments have been developed to treat this disease [2].  
3.2  Stroke Types and Risk Factors 
Most simply, stroke occurs when a portion of the blood flow to the brain is 
diminished or blocked, resulting in cell death, including both necrosis, apoptosis, 
and other mixed cell death phenotypes. There are two main types of stroke: 
hemorrhagic stroke, which results from blood vessel rupture, and ischemic stroke, 
which results from blood vessel occlusion. Hemorrhagic strokes account for about 
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15% of total strokes [62]. Blood from leaking vessels can enter the brain tissue 
(intracerebral hemorrhage, ICH), or the space below the arachnoid layer of the 
meninges (subarachnoid hemorrhage, SAH). ICH is more common than SAH. 
Over 80% of strokes are ischemic and can be categorized based on mechanism 
of blood vessel occlusion. The three primary ischemic stroke types are large artery 
atherosclerosis, cardiogenic embolism, and small vessel occlusion. The non-
modifiable and potentially-modifiable risk factors for hemorrhagic and ischemic 
strokes are listed in (Table 1).  
Table 1. Comparison of important risk factors for hemorrhagic versus 
ischemic stroke. Overall relative risk (RR) noted in left column. Note: This 
list is not exhaustive. See [59, 60, 62-68] for comprehensive lists of risk 
factors. 














Sex (RR male 1.30-
1.37) 
Females during and 
immediately after pregnancy 
Male 
Race/Ethnicity (RR 
1.26-1.81 Black vs 
white) 
Asian > African American > 
Hispanic > White  
African 
American > 









Blood Pressure (RR 
1.25-1.28) 
Hypertension is a well-established risk factor for 



























Atrial fibrillation (RR 
1.6-5.8) 
Not directly associated, 
however, anti-thrombolytic 
(anticoagulation> 






High BMI/Waist-to-hip ratio is associated with 
both stroke types 
Diet (modified 
Alternate Healthy 
Eating Index) (RR  
High mAHEI is negatively associated with both 
stroke types 
Physical Activity (RR 
0.69-0.82) 
Regular physical activity is negatively 
associated with both stroke types 
Alcohol Consumption 
(RR 1.04-1.17) 
Heavy alcohol consumption is associated with 
both stroke types; light/moderate alcohol 
consumption is not associated with ischemic 
stroke, and may be protective [69]  
Numerous mechanisms regarding ischemic stroke pathophysiology have been 
elucidated. Understanding the contribution of each mechanism can inform 
research and the development of novel treatments. Brain tissue is highly 
dependent on oxidative phosphorylation to provide energy, and thus requires high 
amounts of oxygen and glucose. It is estimated that the brain utilizes about 20% 
of the body’s resting metabolism, and about half of that is used to maintain ion 
gradients [70]. Impairment of cerebral blood flow cuts off the delivery of key 
nutrients and oxygen, compromising the energy consumption needed to maintain 
homeostasis. Many cells die as a direct result of ischemic stress. Ensuing 
biochemical and cellular events exacerbate brain damage after the initial hypoxic 
insult. Particularly, improper signaling due to ion imbalance after hypoxia plays a 
significant role in stroke progression. For the following sections, we will describe a 
series of temporal and spatial pathophysiological events that follow ischemic 
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stroke. We also will provide a detailed discussion of the mechanisms that 
contribute to stroke pathology at each stage. 
3.3  Cellular and Molecular Mechanisms in Ischemic Stroke Pathophysiology 
The ischemic stroke region is comprised of two parts. In the core area of the 
ischemic territory, the perfusion deficit results in low ATP. Cellular energy 
homeostasis is disrupted, and cell death develops within minutes. In the penumbra 
region, the area between unaffected and ischemic regions, partially preserved 
perfusion from non-occluded collateral blood vessels allows for milder but still 
significant damage to occur [71]. The core and penumbra regions are spatially and 
temporally dynamic. The penumbra comprises a large portion of the lesion volume 
during the initial stage of blood vessel occlusion [72]. However, if left untreated, 
the penumbra region may become infarcted and the core territory can expand over 
the course of hours and days. It is believed that the core region of the stroke is 
unsalvageable, while the ischemic penumbra is at risk, but still rescuable if 
perfusion is restored [73]. Recent literature has revealed that a select few cells can 
survive in the stroke core, suggesting that the core infarct region is not entirely 
unsalvageable [74]. However, the majority of research is targeted at enhancing the 
peri-infarct area with apparent therapeutic opportunity. A cascade of harmful 
events, including excitotoxicity, spreading depolarization, oxidative and nitrosative 
stress, inflammation, and cell death are central to stroke pathology. Understanding 
the mechanisms that underlie brain damage in the stroke core and the ischemic 
penumbra may direct research on future treatments.  
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3.3.1 Excitotoxicity, Calcium Dysregulation, and Ion Imbalance 
Oxygen and glucose supply is impaired during the immediate perfusion deficit 
following stroke. This deficit compromises the energy supply required to maintain 
normal ionic gradients in neurons and glia. As a result, these cells can lose 
membrane potential resulting in depolarization events. Depolarization causes 
voltage-dependent calcium channel activation and excitatory amino acid (mainly 
glutamate) release into the extracellular space. Concurrently, presynaptic reuptake 
of glutamate is reduced due to the lack of energy needed to activate ion pumps, 
which further exacerbates the increased extracellular glutamate concentration. 
The excess glutamate binds AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid) and NMDA (N-methyl-D-aspartate) receptors to increase the influx 
of water, sodium, and calcium into neurons, inducing a host of signaling events 
that cause cell swelling, activation of catabolic activity, and eventual cell death [75, 
76]. Massive calcium influx initiates a series of cytoplasmic, nuclear, and 
mitochondrial events that directly contribute to the development of tissue damage, 
for example, via activation of proteases [77]. Uncontrolled activation of calcium-
dependent enzymes leads to further ATP depletion and accelerates cell death. 
Acutely, calcium can activate phospholipase A2 to generate free radical species 
which cause membrane damage. Oxygen radicals can also contribute to 
inflammation and apoptosis, as will be discussed below. Calcium-induced 
activation of neuronal nitric-oxide synthase (nNOS) and other Ca2+-dependent 
enzymes causes nitric oxide (NO) and superoxide production, which further 
promote cell death and tissue damage. Mitochondria, an important source of 
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reactive oxygen species (ROS), are also involved in acute cell toxicity [73, 78]. 
Aside from damaging cell membranes and proteins, free radicals also arrest 
energy production, further disrupting energy homeostasis. Calcium release from 
the dysfunctional mitochondria further exacerbates intracellular calcium signaling. 
Cell to cell interactions may also contribute to the spread of excitotoxicity as 
indicated by the apparent role of gap junctions in NMDA receptor mediated 
neuronal death [79]. While the glutamate toxicity hypothesis has been validated in 
laboratory settings, clinical trials targeting the NMDA and AMPA receptors have 
yielded negligible results [80]. It is likely that the cell death processes are far more 
complex than can be described by glutamate toxicity alone. The NMDA-AMPA 
pathway is only one player in the ion balance dysregulation following stroke. 
Indeed, many other ion channels have been implicated in calcium accumulation 
and toxicity. Sodium-calcium exchangers, gap junctions, volume-regulated anion 
channels, transient receptor potential channels, acid-sensing channels, and other 
non-selective cation channels contribute to ion imbalance [76, 81]. There is ample 
space for research on the influence of specific receptors to ion imbalance after 
acute infarction, and how targeting these receptors may provide therapeutic 
benefits.  
3.3.2 Spreading Depolarization and Spreading Ischemia 
As discussed above, ischemic neurons depolarize due to a lack of energy supply, 
and subsequently depolarize to release glutamate and potassium. Spreading 
depolarization describes a sustained depolarization of neurons, which is effectively 
a short circuit between neurons and the extracellular space [82]. This 
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depolarization is accompanied by cell swelling and dendritic spine distortion [83]. 
Direct gap junction mediated connections between neurons may facilitate 
spreading of depolarization [82]. Under pathological conditions such as stroke, the 
normal hemodynamic response to depolarization, namely vasodilation associated 
with neurovascular coupling, can become inverted. Thus, rather than dilating, 
arterioles may constrict to reduce blood flow, termed spreading ischemia [82]. 
Increases in extracellular cations (primarily potassium) and decreases in nitric 
oxide, augment vasoconstriction and reduces vasodilation. The ensuing spreading 
depolarization-induced ischemia creates a vicious cycle where supply of metabolic 
substrates is reduced and demand is simultaneously increased. Spreading 
depolarization is known to occur in the ischemic penumbra and may contribute to 
lesion progression [84, 85]. Each successive spreading depolarization can cause 
enlargement of the stroke area [85]. It has been suggested that targeting the 
inverse microvascular response to spreading repolarization may be a useful 
therapeutic intervention, since targeting depolarization has failed thus far [80, 82, 
83, 86].   
3.3.3 Oxidative and Nitrosative Stress 
Oxidative and nitrosative stress also contribute to ischemic stroke pathology. 
Oxidative and nitrosative free radicals are byproducts of cellular metabolism and 
are normally removed by endogenous antioxidant enzymes and chemicals such 
as superoxide dismutase (SOD), glutathione peroxidase, catalase, ascorbic acid, 
and α-tocopherol [78]. In the injured brain, radical species are extremely harmful 
since endogenous antioxidant enzymes and vitamin concentrations are not high 
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enough to counteract excess radical formation [87]. The brunt of mitochondrial 
reactive oxygen species generation is believed to occur during reperfusion. 
Ischemia-induced post-translational modification of proteins in the oxidative 
phosphorylation pathway prime mitochondria for excessive activity upon the 
reintroduction of oxygen [88]. This hyperactive state could lead to a surge of ROS 
during reperfusion, overwhelming endogenous protective mechanisms. Excess 
ROS can directly damage proteins, nucleic acids, lipids, and carbohydrates to 
promote cell death. ROS can also be generated via NMDA receptor induced 
NADPH oxidase activation [89]. This pathway may be important acutely after 
ischemia during the excitotoxicity phase. Nitric oxide (NO) is a free radical and an 
important cellular signaling molecule involved in many physiological and 
pathological processes. However, excess NO can be directly and indirectly 
neurotoxic. Similar to ROS, reactive nitrogen species (RNS) are harmful to cellular 
components and can induce neuronal death [90]. NO can react rapidly with 
superoxide to generate the strong oxidant peroxynitrite, which is extremely 
cytotoxic [91]. NOS activity and NO production are increased in the ischemic brain, 
leading to increased peroxynitrite production and ensuing cellular damage. RNS 
are known to contribute to breakdown of the blood brain barrier (BBB) via activation 
of matrix metalloproteinases (MMPs) [91, 92]. Taken together, ROS and RNS are 
damaging neurotoxic agents that intensify ischemic damage after reperfusion. 
Targeting these reactive chemicals may be useful in reducing side effects after 
administration of tPA and the resulting reperfusion [91, 93].  
3.3.4 The Inflammatory and Astrocytic Response to Cerebral Infarction 
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Inflammation plays an important role in the pathogenesis of ischemic stroke. After 
an ischemic insult, several key transcriptional factors, such as hypoxia inducible 
factor 1 (HIF-1), nuclear factor-κB (NF-κB), interferon regulatory factor 1 (IRF1), 
and signal transducer and activator of transcription (STAT3), are up-regulated via 
calcium-induced signaling pathways, increased oxygen free radicals, and hypoxia 
[94-96]. These transcriptional factors induce the expression of numerous pro-
inflammatory genes, including tumor necrosis factor α (TNFα), interleukin 1α (IL-
1α) and 1β (IL-1β), intercellular adhesion molecule 1 (ICAM-1), and selectins [75, 
94, 97]. Circulating leukocytes interact with these adhesion molecules to adhere 
to brain endothelium, transmigrate through the vascular wall, and enter the brain 
parenchyma. Neutrophils are thought to be the first leukocytes to infiltrate after 
ischemic stroke, and can be found as early as 30 minutes after focal ischemia [98]. 
Peak infiltration is on the order of days (1-3 days), and may continue to remain in 
the ischemic area for weeks [99]. This initial infiltrate amplifies the inflammatory 
response by releasing cytokines and chemokines, activating matrix 
metalloproteinases, and producing ROS. These effects are primarily negative and 
can result in BBB disruption, edema, neuronal death, and hemorrhagic 
transformation [94, 96-98, 100]. However, at later stages, neutrophilic infiltration 
may promote recovery and regeneration, for example, via MMP-9 mediated 
neurovascular remodeling [94, 98, 100, 101].  
Circulating macrophages and endogenous brain microglia also play dual 
roles in recovery by expressing anti- and pro-inflammatory mediators. Resident 
microglia respond initially (within hours following infarction), while blood-derived 
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macrophages infiltrate later, by 3 days [98, 101, 102]. They continue to accumulate 
over the course of weeks [98, 102]. A number of studies suggest that the majority 
of macrophages in the ischemic brain are derived from resident microglia, and that 
the relative contribution of circulating versus resident macrophages needs further 
evaluation [98]. Traditionally, microglia/macrophages have been thought to 
demonstrate two primary phenotypes: “classically activated” M1 (pro-
inflammatory) and “alternatively activated” M2 (protective/trophic support) 
subtypes [102, 103]. There is likely a significant overlap between these subtypes 
and a growing body of research indicates microglia/macrophages have an 
incredibly diverse range of biological functions following brain damage which is 
outside the scope of this review [98, 100, 102-106]. The M2 phenotype is primarily 
restorative, and can promote processes such as neurogenesis, axon growth and 
remodeling, vessel growth and infiltration, and myelination processes [102]. 
Initially after stroke, they are responsible for clearing cellular debris and infiltrating 
neutrophils [98]. The M1 phenotype is primarily pro-inflammatory. For example, 
they can exert neurotoxic effects via the production and release of cytokines (i.e. 
IL1-β, IL-6, TNF-α), ROS, and MMPs [102, 106, 107]. Initially, the injury site is 
dominated by M2 macrophages; however, M1 macrophages dominate after about 
1 week [102]. This M2-to-M1 transition may create an unfavorable 
microenvironment for repair and can last for weeks after injury [102]. 
Astrocytes are the most abundant cell type in the brain. Similar to other 
players in neuroinflammation, astrocytes play a dichotomous role in both damage 
and regeneration after stroke. They are able to form barriers between the CNS 
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parenchyma and non-neural tissue, for example, along brain vasculature and the 
meninges [108]. After stroke, astrocytic scars, formed mainly of newly proliferated 
astrocytes, create an interface between viable CNS parenchyma and the core 
infarct region [108-111]. Within a couple days after ischemia, astrocytes become 
reactive, exhibiting stellate morphology and expression of glial fibrillary acidic 
protein (GFAP) [109, 110]. The glial scar acts as a protective functional barrier that 
prevents the spreading of toxic inflammation [108]. Early after stroke, astrocytes 
appear to play a primarily neuroprotective role [108, 111-113]. Disruption of scar 
formation after stroke allows for the spread of neuroinflammation and results in 
greater loss of neurons, increased lesion size, and decreased function [108-112]. 
However, during the recovery phase after ischemic insult, the astrocytic scar is 
thought to be inhibitory to axonal growth and is associated with reduced neural 
regeneration and functional recovery [111, 112, 114, 115]. Contrary to this binary 
dogma, a growing body of research suggests the astrocyte scar can play a role in 
axonal recovery [116]. Further research is needed to clarify the role of the glial scar 
in healing after stroke, and its relation to potential therapies.  
The inflammatory mechanisms that occur in response to stroke are complex 
and exhibit dichotomies that can best be explained temporally. Detailed research 
is needed to tease apart the contributions of individual cell types across both time 
and space relative to infarction. Careful consideration of the cellular inflammatory 
responses must be accounted for in the development and evaluation of stroke 
treatments. Optimal treatment would attenuate the negative effects of 
neuroinflammation while preserving or accentuating the positive effects.  
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3.3.5 Cell Death after Cerebral Ischemia 
Cell death pathways are at the heart of stroke pathophysiology. Multiple modes of 
cell death are evident in stroke. Traditionally, these mechanisms were separated 
into apoptosis, or controlled cell death, and necrosis, or unregulated cell death 
[117]. Apoptosis involves the organized dismantling of cells to minimize damage 
to neighboring cells, while necrosis leads to release of intracellular debris which 
can stimulate inflammatory responses and damage surrounding cells through 
various mechanisms, for example, by generating excess ROS [118, 119]. We now 
understand there is considerable overlap between these pathways, and that 
necrotic cell death can be regulated (termed necroptosis, programmed necrosis, 
or caspase-independent programmed cell death) [75, 118-124]. Autophagy, a 
lysosomal processes of cellular component recycling, is intimately associated with 
both cell death and survival mechanisms in ischemia [122, 123, 125-130]. In fact, 
apoptosis, autophagy, programmed necrosis, and necrosis all occur in stroke, and 
some cells even exhibit multiple mechanisms simultaneously [74, 124, 131]. 
Recent literature suggests that after about 1 day post-stroke in the core region, 
around 70% of cells show signs of necrosis while 30% appear apoptotic, and 
autophagy is also concurrently activated in both of these cell death pathways [74].  
There are two primary pathways of apoptosis in cerebral ischemia: 1) the 
intrinsic pathway, which initiates via mitochondrial release of cytochrome-C and 
activation of caspase-9, and 2) the extrinsic pathway, which commences with the 
activation of cell surface death receptors and caspase-8 [117, 118, 121]. Both of 
these pathways eventually converge to activate the executioner proteases 
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caspase-3 and -7 which drive proteolysis [117, 118, 121]. Ultrastructural evidence 
indicates that during apoptosis, the nucleus and other cellular organelles are 
condensed and fragmented into smaller parts [117, 118]. DNA is also hydrolyzed 
into many fragments. Finally, phagocytes ingest apoptotic bodies with minimal 
release of inflammatory cytokines [117, 121, 122]. Necrosis is caused by 
overwhelming stress (i.e. acute hypoxia in stroke), resulting in unregulated cellular 
demise [75, 118, 121, 124, 132]. Nuclei appear swollen, ROS are generated, and 
cellular membranes begin to disintegrate to allow the release of inflammatory 
cellular contents into the extracellular space [118, 119, 124, 127]. Contrary to 
apoptosis and necrosis, programmed necrosis is highly regulated but occurs 
independently of caspase signaling, and is instead mediated via receptor-
interacting protein1 (RIPK1) [120-122, 133]. Activation of death receptors by TNFα 
and FasL are also involved in programmed necrosis [119-121, 133]. In an 
evolutionary sense, programmed necrosis is believed to provide defense against 
intracellular pathogens that block apoptosis activation [121]. Necroptosis has been 
documented in stroke, but its significance needs further study [76, 78, 118, 134, 
135].  
A number of morphological studies have elucidated the roles of apoptosis 
and necrosis after ischemic injury. Wei et al used a series of chemical and 
immunohistological methods, including 2,3,5-triphenyltetrazolium chloride (TTC) 
staining, hematoxylin–eosin (H&E) staining, terminal deoxyribonucleotidyl 
transferase-mediated dUTP nick end labeling (TUNEL), and caspase-3 staining, 
and ultrastructural examination to study cell death mechanisms in the ischemic 
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cortex and non-ischemic thalamus after cortical focal ischemia [124]. They showed 
that the morphology of TUNEL+ cells in the ischemic core were primarily necrotic, 
whereas TUNEL+ cells in the thalamus and cortical penumbra exhibited both 
necrotic and apoptotic morphology [124]. Isin et al also examined cell death 
patterns after transient and permanent focal ischemia to show that apoptosis and 
necrosis, or a mixed/hybrid phenotype, can occur in the same cells [135]. They 
suggest that the ischemic neuronal cell death phenotype may be determined by 
the relative speed of apoptotic versus necrotic processes [135]. Jiang et al 
performed a detailed analysis of the stroke core to show that apoptosis is a 
significant mechanism of cell death in the ischemic core, with up to 30% of cells 
undergoing programmed cell death [74]. These findings need further clarification 
regarding the role of programmed necrosis in cellular demise.  
Autophagy is a well-known player in cellular homeostasis. Superfluous or 
damaged proteins and organelles are packed into autophagosomes, which drain 
into lysosomes for degradation [122, 123, 134, 136]. The role of autophagy in cell 
death, particularly in ischemic cell death, is controversial and under intense study. 
The effects of autophagy are likely context dependent. Numerous studies have 
demonstrated that autophagy is activated following ischemic insult [123, 126-128, 
136-138]. Whether autophagy is a driver of cell death in ischemia is still not 
clarified. Some experimental evidence suggests that reducing autophagy early 
after infarction can attenuate injury progression [136, 139-141]. Conversely, other 
studies indicate that promoting autophagy may induce cells to undergo apoptotic 
rather than necrotic cell death, leading to reduced lesion sizes [136, 142, 143]. 
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Inadequate autophagy may also contribute to cell death in stroke [144]. It is 
conceivable that a moderate amount of cellular component recycling, particularly 
in the acutely hypoxic stages of stroke, may provide neurons with a larger 
physiologic reserve thereby allowing the cells to sustain ischemic damage. It is 
equally conceivable that digesting valuable cellular components in response to 
hypoxic insult, when the cell needs them the most, can lead to cell demise. This 
view is consistent with observations that apoptosis and autophagy appear to 
predominate in the penumbra, where cells may exhibit a physiologic reserve large 
enough to sustain the initial ischemic insult, and necrosis appears to predominate 
in the core region, where autophagy may be more associated with cell death [74, 
123, 126, 127, 129, 134, 145]. Future research on autophagy and its role in 
ischemic cell death must place special consideration to location (i.e. infarct versus 
peri-infarct regions) and timing after stroke.  
3.4  Stroke Prevention and Treatment 
Primary prevention is the optimal method for reducing stroke burden since nearly 
80% of strokes are first events. Modifiable risk factors such as those listed in Table 
1 can be readily identified in stroke prone patients [60]. The AHA/ASA guidelines 
for primary prevention of stroke provide detailed recommendations with special 
weight towards modifiable risk factors. They provide evidence based 
recommendations on physical activity, dyslipidemia, hypertension, obesity, 
diabetes, cigarette smoking, and other cardiovascular conditions [60].  
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For those who have already suffered ischemic stroke, rapid administration 
of tissue plasminogen activator (tPA) within 4.5 hours of stroke onset is the 
mainstay of treatment [146]. tPA acts to dissolve the blood clot, directly improving 
blood flow to the perfusion-deficient area of the brain. There are benefits with 
earlier tPA administration [146, 147]. Beyond this narrow time window, treatment 
with tPA is not effective and its side effects, primarily bleeding, outweigh the 
marginal benefits [146, 147]. Mechanical thrombectomy within 6 hours of disease 
onset is another option for the treatment of acute ischemic stroke, and should be 
performed after treatment with tPA when indicated [146]. Recent clinical trials, 
including the DAWN and DEFUSE 3 trials, have indicated a clear benefit for an 
extended window of up to 24 hours for mechanical thrombectomy in certain 
patients with large vessel occlusion [148]. The results from these clinical trials are 
reflected in the 2019 Society of NeuroInterventional Surgery (SNIS) 
recommendations [149].  As with tPA, earlier surgical treatment is associated with 
greater benefits. Secondary prevention of patients who have already experienced 
stroke is another important method to reduce stroke burden [64]. Similar to primary 
prevention, secondary prevention focuses on control of risk factors, and special 
attention is paid to antiplatelet therapy [64].  
3.5  The Role of Collateral Circulation in Ischemic Stroke Pathophysiology 
The primary pathological feature of ischemic stroke is vessel blockage and loss of 
cerebral blood flow, resulting in tissue death. Collateral circulation, or the network 
of vascular channels that stabilize cerebral blood flow after a principal conduit fails, 
is a crucial determinant of ischemic stroke severity, progression, and recovery 
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[150]. The progression of brain tissue damage after artery occlusion is inversely 
correlated to the amount of residual blood flow. The cerebral vessel network is 
complex and consists of plexuses of cortical arteries, arterioles, penetrating 
arterioles, capillaries, venules, and veins. The connections at the Circle of Willis 
and anastomoses between terminals of major artery trees (for example, the 
leptomeningeal and pial anastomoses) ensure the penetrating arterioles can be 
sourced rapidly by blood flow from other regions when occlusions take place. While 
the hemodynamics of collaterals and their relationship to tissue perfusion has not 
been fully explored, the compensatory effect is evident for their significant role in 
stroke prognosis, infarct progression, and tissue fate after reperfusion in acute 
ischemic stroke (AIS) ascribed to large artery occlusion [151]. 
3.5.1 Collateral Circulation Dynamics during Ischemic Stroke 
The leptomeningeal collateral channels are believed to be recruited immediately 
after AIS due to the formation of a pressure gradient caused by arterial occlusion. 
However, collateral flow can be highly variable in the hours, days, and weeks after 
stroke. A number of studies have highlighted changes in collateral circulation 
patterns and their relevance to outcomes in acute stroke patients. In a study 
including patients who did not undergo reperfusion 3-5 days after AIS, Campbell 
et all showed that deterioration in collateral quality is associated with infarct growth 
[152]. Using laser speckle imaging, Wang et al described three kinds of dynamic 
changes in leptomeningeal arteriole flow after middle cerebral artery occlusion: 
persistent LMAs, impermanent LMAs, and transient LMAs [153]. Persistent LMAs 
were patent observable over 3 hours, while impermanent LOs diminished after 90-
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150 minutes, and transient LMAs that were no longer observable after 90 minutes. 
An early study in monkeys by Meyer et al found that after MCA occlusion, collateral 
flow can vary to meet the metabolic needs of the ischemic tissue; however the 
collateral flow is variable, and eventually stabilizes after ~2 weeks [154]. 
Importantly, these dynamic changes in collateral circulation were correlated to 
changes in regional blood flow. Some proposed mechanisms of collateral collapse 
include blood pressure reduction, dysfunction of auto-regulation, collateral vessel 
thrombosis, and venous steal. While collateral failure is known to be associated 
with infarct progression, it is unsure whether the effect is causative. These studies 
suggest that targeting collateral flow during the initial stages of AIS may be a viable 
therapeutic strategy. 
3.5.2 Collateral Circulation and Stroke Severity 
The amount of collateral circulation is related to functional outcomes in the natural 
history of anterior circulation large artery occlusion. In a prospective study of 126 
untreated patients with anterior circulation large artery occlusion, Lima et al [155] 
found that the pattern of leptomeningeal collaterals assessed by conventional CT 
angiograms (CTA) were independent predictors of good clinical outcome on 6 
months follow up. In another study, Seyman et al [156] found that the 
compensatory ability of collaterals in AIS patients (<12 h) is inversely correlated 
with final cortical infarct volume and long term modified Rankin Scale (mRS) score. 
A post-hoc analysis of data from the Warfarin-Aspirin Symptomatic Intracranial 
Disease (WASID) study also revealed increased risk of ischemic stroke in patients 
with poorer collaterals. However, the absolute relationship between collateral 
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grade, baseline severity, and infarction volume remains controversial. For 
instance, in one study involving AIS patients who underwent emergent 
endovascular treatment, there was no significant association between collateral 
grade and pretreatment infarct volume or National Institutes of Health Stroke Scale 
(NIHSS) score [157-159]. In another study which enrolled 60 patients with anterior 
circulation AIS (<12 h), there was no difference in the rate of good functional 
outcomes in patients with poor or good collaterals after reperfusion [160]. These 
conflicting studies suggest the significance of collateral grade on stroke severity 
may be time-dependent, or might rely on if and when reperfusion is achieved.   
3.5.3 Collateral Circulation, Infarct Progression, and Tissue Fate after 
Reperfusion 
The extent of viable collateral channels to the infarct region is an important factor 
in infarct development and response to reperfusion therapy. Cheripelli et al [161] 
examined the collateral state and penumbra volume of 144 AIS patients within 6 
hours of stroke onset. The patients were grouped according to duration from stroke 
onset to brain imaging time. While there was little significant association between 
penumbra volume over time in patients with good collaterals, there was a trend 
towards reduction in penumbra proportion among those with poor collaterals [161]. 
This suggests that targeting the salvageable penumbra region may provide greater 
benefits for patients with poor collaterals. Collateral quality is strongly correlated 
with the rate of penumbra tissue loss during the early stages of stroke progression. 
Jung et al [159] collected data from 44 AIS patients with M1 or M2 occlusion and 
calculated the rate of penumbra tissue loss using sequent MRI images. In patients 
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who were successfully reperfused (without complication), there was a strong 
association between collateral quality and total penumbral tissue loss. Patients 
with poor collaterals (grade 0) lost 27% of their penumbral tissue, while patients 
with grade 1 lost only 11%, and patients with good collaterals actually saw an 
increase in their penumbra volume (-2% loss). Likewise, the rates of penumbral 
tissue loss were also associated with collateral quality. They concluded that rich 
collaterals can remarkably slow penumbra tissue loss and potentially extend the 
therapeutic window for reperfusion treatment [159]. This is supported by evidence 
linking residual blood flow and oxygen metabolism/extraction to the ability to 
salvage hypo-perfused brain tissue after infarction [162]. Using positron emission 
tomography studies in a swine model, Sakoh et al showed that animals subjected 
to only mild hypo-perfusion showed no oxygen-metabolism deficiencies within 6 
hours, while moderately and severely ischemic tissues lost viability after only 3 and 
1 hours, respectively [162]. 
Our understanding of the significance of cerebral collateral circulation has 
grown due to the increasing prevalence of reperfusion therapy following acute 
ischemic stroke. The benefits of reperfusion are magnified in patients with good 
collaterals. A meta-analysis of 2652 subjects who received endovascular 
reperfusion showed that patients with good collaterals had higher rates of 
favorable outcomes, reduced risks of peri-procedural symptomatic intracranial 
hemorrhage, and reduced 3 month mortality compared to patients with poor 
collaterals [163]. Another study showed that poor collateral circulation is a predictor 
of malignant infarction after reperfusion therapy [164]. In a study involving a cohort 
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of 207 AIS patients with M1 occlusion that received endovascular treatment within 
8 hours, a shorter onset-to-reperfusion time was significantly associated with 
higher rate of favorable outcomes in those with poor collaterals, but the difference 
was not significant in the group with good collaterals [165]. Taken together, these 
studies suggest that patients with good collaterals appear to have a longer time 
window for reperfusion therapy, and those with poor collaterals were more likely to 
have dramatic reversion of functional outcome after prompt reperfusion [160]. 
Importantly, the beneficial effects of collateral blood flow are only prominent in 
patients who achieve reperfusion [166].  
Recent updates to the AHA guidelines for the early management of AIS 
patients [148] reflect findings on the role of collateral flow in stroke. In short, 
secondary analyses from the MR CLEAN [167] and IMS III [158, 168] trials suggest 
it may be reasonable to incorporate collateral flow status into clinical decision 
making to determine whether or not mechanical thrombectomy should be pursued 
[148]. Furthermore, the DAWN and DEFUSE 3 trials showed that endovascular 
therapy is effective up to 16-24 hours in certain patients [148, 169]. Further clinical 
trials are needed to clarify how collateral status may be used to define treatment 
and extend therapeutic opportunities. 
3.5.4 Therapeutic Strategies to Modulate Collateral Flow 
The viability of cerebral collateral flow after acute proximal artery occlusion 
illustrates the possibility of enhancing collateral flow as a therapeutic strategy to 
preserve tissue before reperfusion. Such methods would effectively convert what 
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would be ischemic core tissue into salvageable penumbral tissue. Clinical trials for 
this strategy are listed in Table 2. As with other neuroprotective strategies that are 
struggling to move from bench to bedside, it is paramount to address the issues 
that prevent collateral enhancement therapy for AIS from translating to the clinic. 
One such effort was performed by Beretta et al [170]. In a preclinical rodent model, 
they investigated four different ‘collateral therapeutics’, including phenylephrine to 
induce hypertension, polygeline to increase intravascular volume load, 
acetazolamide to promote cerebral arteriolar vasodilation, and head down tilt 
(HDT) to encourage cerebral blood flow. They attributed the highest efficacy and 
safety profile to the HDT group. Despite these positive findings in rodent models, 
a recent clinical trial found no significant difference between treatment groups for 
AIS patients (Table 2) [171].  
Table 2. Published clinical trials on collateral enhancement therapy for the 
treatment of acute ischemic stroke. 
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As a whole, preclinical studies suggest that augmenting collateral blood flow after 
acute ischemic stroke remains a promising therapeutic target to preserve the 
penumbra and alleviate ischemic reperfusion injury, particularly in the early stages 
of AIS management. More effort is needed clarify how these findings can be 
applied successfully to stroke patients.  
Very few studies have interrogated collateral dynamics at later timepoints 
when the infarct zone has stabilized. Whether and how therapies may enhance 
collateral recruitment and remodeling during chronic stroke is not fully understood. 
Neovascularization is also very important to recovery after ischemic stroke. Post-
stroke angiogenesis is a recognized phenomenon that occurs in effort to maintain 
long-term tissue remodeling and homeostasis [176]. In a rodent model of ischemic 
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stroke, Wei et al showed that establishment of collaterals after stroke was integral 
to functional recovery [177]. Arteriogenesis and angiogenesis in the penumbra 
region can facilitate later neurogenesis and likely plays a role in neuroplasticity 
[176, 178]. Methods and treatments to promote vascularization after stroke are 
being explored, and endogenous mechanisms of post-stroke neovascularization 
are discussed further in section 3.6.2.  
3.6  Endogenous Repair and Regeneration in the Adult Brain after Ischemic 
Stroke 
3.6.1 Post-stroke Neurogenesis 
Neural stem cells (NCS-A) and neural progenitor cells (NPCs) in the adult brain 
are mainly located in two regenerative niches: the subventricular zone (SVZ) 
flanking the lateral ventricles and the subgranular zone (SGZ) of the dentate gyrus 
(DG) in the hippocampus [179-183]. In rodent models in healthy conditions, 
neurons originating from these two areas have distinct destinies: the neuroblasts 
derived from the SVZ migrate along the rostral migratory stream, become 
interneurons, and integrate with other cells in the olfactory bulb. The newborn 
neurons of the SGZ differentiate and assimilate into the local neural network of the 
hippocampus where they are involved in learning, memory, and mood regulation. 
Interestingly, human SVZ neurogenesis exhibits an evolutionary divergence which 
shows a remarkable difference from other vertebrates. In humans, it was shown 
that long‑distance migration of SVZ‑derived NPCs to the olfactory bulbs is virtually 
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nonexistent, while there is abundant neurogenesis from the SVZ into the adjacent 
striatum [184]. 
Neurogenic activities in the SVZ and SGZ are upregulated following stroke 
[185, 186]. Endogenous NPCs proliferate after ischemia and differentiate into 
neuroblasts and astrocytes, which subsequently migrate along the route from the 
SVZ to the infarct region[187, 188]. Neural progenitor cells from the SGZ do not 
migrate to the infarcted region [189, 190]. The rate of neurogenesis peaks at about 
3-4 weeks after cerebral infarction in both the SVZ and the SGZ, and the migration 
of neural progenitors to the infarct region peaks at 4 weeks [189].  
Accumulating evidence unveils that NPC functions are regulated by 
different signals, which should be taken into consideration when optimizing cell-
based therapies [191-193]. Hypoxic‑ischemic brain injury in neonates induces cell 
death in committed neural precursors but stimulates the proliferation and 
differentiation of immature neural progenitors for brain repair [194]. This suggests 
age may play an important role in the neurogenic potential of both endogenous 
neural progenitor cells and also transplanted cells following stroke. The activation 
of chemokine receptors can increase the number of migrating NPCs. The CXC 
chemokine receptor type 4 (CXCR4), which is the cognate receptor for 
stromal‑derived factor 1 (SDF‑1), crucial for coupling neurogenesis with 
angiogenesis after stroke and directing the migration of neuroblasts to the infarct 
region[195]. In addition, C‑C chemokine receptor type 2 (CCR2), the cognate 
receptor for monocyte chemoattractant protein 1, is upregulated in migrating 
neuroblasts following ischemia and is critical for proper destination targeting [196]. 
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Neurotrophic and growth factors also play important roles in the regulation 
of adult regeneration, including, but not limited to, granulocyte‑colony‑stimulating 
factor (G‑CSF), insulin growth factor (IGF-1), glial cell‑derived neurotrophic factor 
(GDNF), and brain‑derived neurotrophic factor (BDNF) [196-199]. G‑CSF and 
IGF‑1 can reduce NPC death through altering key survival pathways (e.g., the 
phosphoinositide 3 kinase‑Akt pathway). Several recent clinical trials 
demonstrated the ability of G‑CSF to both mobilize endogenous bone marrow cells 
and exert its neuroprotective effects to promote stroke recovery [197]. In addition 
to growth factors, anti‑inflammatory drugs such as indomethacin, noncoding RNA, 
and hormones can also increase endogenous NPC proliferation [200, 201]. 
Together, these studies corroborate the principle that factors which promote 
neurogenesis might contribute to better cell-based therapies for neurological 
disorders such as ischemic stroke. 
However, the efficiency of endogenous neural regeneration is extremely 
limited, and is insufficient in itself for effective repair of damaged brain tissue [202]. 
For example, in a striatum stroke model, about 80% of newly formed neurons fail 
to survive, and endogenous neuronal regenerations replaces only ~0.2% of 
neurons lost to stroke [190]. Therefore, it is imperative to discover strategies which 
can augment neuronal replacement efficiency. Identification and modification of 
inhibitory factors and enhancement of contributory factors might help to augment 
the brain’s adaptive endogenous regeneration to various neurological disorders 
and improve cellular therapy-mediated brain repair. 
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3.6.2 Vascular Regeneration and Remodeling after Ischemic Stroke 
Neovascularization is a hallmark of tissue recovery after ischemic insult [203]. 
Angiogenesis is defined as the growth of new vessels from pre-existing 
vasculature, while vasculogenesis is the de novo formation of new blood vessels 
from vascular progenitor cells [204]. While both have been described in stroke, 
angiogenesis, and in particular endothelial sprouting, is thought to be the primarily 
method of neovascularization following ischemic injury in adults [176, 195, 203, 
204].  Angiogenesis is a key player in the regenerative process, and allows for 
increased blood flow and nutritional support to areas of hypoxia, and also facilitates 
restoration of the neurovascular network [176, 195, 203, 205]. Angiogenic 
mechanisms are induced by hypoxia [178, 203, 206]. The major angiogenic 
molecules, including vascular endothelial growth factors (VEGF), fibroblast growth 
factors (FGF), platelet-derived growth factors (PDGF), transforming growth factors 
(TGF), and also angiogenic chemokines stromal cell-derived factor 1 
(CXCL12/SDF-1), as well as many of the cognate receptors for these molecules, 
are induced by hypoxia, and in many cases, directly or indirectly by hypoxia 
inducible factor (HIF-1) [178, 203, 206-210]. Angiogenesis following ischemic 
stroke occurs primarily in the peri-infarct region, although, some have reported 
angiogenesis in the stroke core region as well [74]. Peri-infarct angiogenesis 
persists for weeks after the initial ischemic insult [211]. 
A growing body of evidence supports the ‘vascular niche’ hypothesis that 
neural precursors in the adult brain are associated with an angiogenic environment 
[176, 195, 203]. Neuroblast migration relies heavily on the scaffolding provided by 
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blood vessels [13]. Capillaries in the infarct region release chemoattractant factors 
such as SDF-1 and Angiopoietin-1 which promote migration of neural progenitors 
from the SVZ [195]. Under healthy conditions, a large proportion of neuroblasts 
migrating along the rostral migratory stream are in close proximity to or in contact 
with the vasculature [212]. In line with the neurogenic ‘vascular niche’ hypothesis, 
some groups have shown that angiogenic therapies can promote neurogenesis 
and formation of new axons along newly generated blood vessels [49].  
The remodeling of existing vasculature is also an important recovery 
mechanism following ischemia. Arteriogenesis, or the remodeling of pre-existing 
arteries to facilitate greater flow, plays a major role in stroke recovery. Fluid shear 
stress is the primary driver of arteriogenesis, and following cerebral infarction, 
shear stress is increased when flow is diverted away from the blocked vessel into 
collateral channels [205]. Positive outward remodeling of the vasculature is a major 
mechanism of arteriogenesis, and results in larger capacity for blood flow [176, 
205, 206]. The mean diameter of both microvessels and large arteries increases 
in the peri-infarct region following stroke [153, 213].  
The molecular and physical mechanisms of arteriogenesis involve 1) 
mechanical force via increased fluid shear stress and circumferential wall stress, 
2) endothelial activation, 3) inflammation, and 4) structural remodeling [176]. 
Within these mechanisms of arteriogenesis, the stroke field most commonly 
focuses on the inflammatory response since it is most readily observable and 
therapeutically modifiable [176]. The monocyte chemoattractant protein-1 (MCP-
1) is the major player for monocyte recruitment in arteriogenic inflammation [176, 
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205, 206]. These recruited arteriogenic macrophages (and brain-resident 
microglia) produce and release growth factors such as bFGF, TGF-B, and 
chemokines including MCP-1, CCL3, CCL4, and SDF-1. The infiltrated 
macrophages/microglia also remodel the extracellular matrix by production of 
matrix metalloproteinases  [205, 207, 208]. These factors promote proliferation of 
endothelia and smooth muscle cells to facilitate vessel outward remodeling and 
expansion of collateral diameter [208, 214].  
3.7  Mouse Ischemic Stroke Models 
A number of rodent stroke models have been developed for preclinical studies. 
The table below, adapted from [13], summarizes the procedures and major 
benefits/drawbacks for each stroke model. Small ischemic strokes are the most 
common type of strokes seen in the clinic [148]. Therefore, increasing efforts have 
been made to study smaller strokes in animal models. Furthermore, the mini-stroke 
models are thought to be most useful for morphological examinations of structural 
repair in the mouse, and thus, are the most useful for assessing the effects of 
cellular therapy. The mini-stroke model often involves surgical occlusion of distal 
branches of the MCA. Other variations, including permanent ligation of the MCA 
coupled with bilateral CCA occlusions have also been described, and the infarcts 
produced are similar [13]. These branches feed the sensorimotor cortex, including 
the well-described barrel cortex, which is responsible for whisker function [177, 
215, 216]. The whisker-thalamus-sensorimotor cortex neuronal pathways are 
prominent in rodents and a multitude of sensorimotor functional tests have been 
developed to interrogate the integrity of this pathway [217, 218]. Thus, the 
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sensorimotor cortex stroke models are ideal for examining the intracortical and 
thalamo-cortical neuronal morphological recovery, and importantly, the potential 
effects of treatment on sensorimotor recovery.  
Table 3. Rodent Stroke Models 
Model Procedure Benefits/Drawbacks References 
MCA Occlusion 
Reversible 
occlusion of the 
proximal MCA 
with variable size 
suture 
 Severe damage and 




 Difficult to evaluate 
regeneration at 
structural and network 
levels due to stroke 
severity 











 Stroke limited to cortex 
(most often the 
sensorimotor cortex) 










and occlusion of 
irradiated 
vessels 
 Non-invasive; wake 
animals 
 Local ischemic injury 
with minimal penumbra 
formation 









 Local ischemic injury 
with minimal penumbra 
formation 








3.8  Stem Cell Therapy for Ischemic Stroke 
3.8.1 Stem Cell Sources for Cellular Therapy 
Stem cells are major sources of cell‑based therapy. They can be classified as 
totipotent cells, naïve pluripotent stem cells, primed pluripotent cells, and 
tissue‑specific multipotent stem cells. Totipotent cells, characteristic of the zygote 
and early blastomeres, can develop into all tissues, including extra‑embryonic 
tissue. While both naïve and primed pluripotent cells can form teratomas, the two 
different pluripotent states have distinct molecular differences. Naïve stem cells 
are in a ground state, harboring the prerequisite potential to differentiate into all 
embryonic lineages and develop into chimeric blastocysts. They possess high 
clonogenicity and do not carry specification markers [227]. Primed pluripotent cells, 
which do not produce chimeras, express FGF‑5 specification marker and have low 
clonogenicity. For pluripotency markers, naïve stem cells display greater levels of 
pluripotency marker proteins, including OCT‑4, NANOG, SOX‑2, KLF‑2, and 
KLF‑4, while primed cells lose KLF‑2 and KLF‑4 expression. Aside from the naïve 
and primed pluripotent states, a study discovered an intermediate pluripotent stage 
between the two states [228]. The tissue‑specific multipotent stem cell has the 
least differentiating potency among all stem cell types, with the ability to form 
tissue‑specific cell types [229, 230].  
The success in generation and culture of ESCs from mice, primates, and 
human embryos has been considered a milestone of stem cell research. ESCs are 
a useful tool for exploring early embryonic development, modeling pathological 
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processes of diseases, and developing therapeutics through drug discovery and 
potential cell replacement [231]. Human ESCs (hESCs) now hold a great promise 
for regenerative medical treatments as the cells can generate any cell type of the 
body. Human ESCs are mainly defined as primed pluripotent cells, which are 
different from and show less plasticity than the murine ESCs. It remains unclear 
whether human‑naïve pluripotent stem cells, obtained either by continued 
transgene expression or through specific chemical manipulation of the culturing 
microenvironment, are analogous to mouse counterparts [232-234]. Nevertheless, 
it is worthwhile to validate the findings from these reports using naïve human ESCs 
generated from different strains and laboratories in future studies. 
Differentiation of ESCs in vitro has been achieved at very high efficiencies 
into various transplantable progenitors/precursors and terminally differentiated 
neuronal and glial cell types, which include cortical glutamatergic, striatal 
GABAergic, forebrain cholinergic, midbrain dopaminergic, serotonergic, and spinal 
motor neurons, as well as astrocytes and oligodendrocytes [235-241]. These 
differentiated cells, including neurons, astrocytes, and oligodendrocytes, have 
been exogenously transplanted and evaluated in animal models. Translation into 
the clinic is ongoing for various neurological disorders, including: (1) PD, in which 
nigro‑striatal neurons are lost before other neurons, (2) HD, in which MSNs are 
lost, resulting in striatal atrophy, and (3) glial and myelin disorders [242-244]. Other 
disorders, including AD and Lewy body disease, which involve a multitude of 
neuronal cell types, and amyotrophic lateral sclerosis (ALS) and spinal muscular 
 41 
atrophy, which are multicentric and diffuse neurodegenerative disorders, remain 
poor targets for stem cell‑based therapies.  
Induced pluripotent stem cells (iPSCs) are pluripotent cells that are 
artificially de‑differentiated from adult somatic cells by several transcription factors 
or small‑molecule compounds and have ignited the field of lineage reprogramming 
[245, 246]. There are epigenetic differences between iPSCs and ESCs, which 
include expressions of unique genetic signatures, teratoma formation capacity, 
and the differentiation potency and flexibility (e.g., dissimilar differentiation 
potential into various transplantable neural cells [247, 248]). Furthermore, 
compared to ESCs, iPSCs can be more amenable as donor cells for cell 
replacement therapy, in vitro disease models, and drug screening [247, 249]. First, 
iPSCs are derived from adult somatic cells, which can be easily obtained from 
patients, and then banked and stored. Second, cultures of hiPSCs and hESCs are 
technically similar, but the generation of iPSCs harbors much less ethical concern 
and opposition. Third, given the somatic cell source and the autologous nature of 
iPSCs, cell therapy using iPSCs should have no immune rejection in theory, or at 
least minimize the risk of immune system rejection. However, a recent report 
suggests that some unusual gene expressions in transplanted cells derived from 
the iPSCs may trigger an immune response [250]. 
Mesenchymal stem cells (MSCs) derived from the bone marrow, umbilical 
cord blood, and adipose tissue can exert immunomodulatory and 
anti‑inflammatory effects in CNS disease models such as stroke and MS [251, 
252]. Overexpression of some neurogenic/angiogenic factors such as VEGF in the 
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transplanted MSC cells might help improve memory and induce 
neovascularization/neurogenesis within the adult brains [252]. Clinical trials 
demonstrated safety and feasibility of MSC transplantation in acute and chronic 
stroke with no tumorigenicity reported following cellular transplantation [251]. 
However, despite the ability of MSCs to exhibit significant plasticity reflecting a 
stem-like phenotype in vitro, some studies suggest that MSCs do not behave as 
tissue-specific progenitors in vivo, and rather, may take on a pericyte-like 
phenotype following transplantation or even endogenously [253, 254].  
Fetal NPCs, which can differentiate into functional neurons and multiple 
types of neuroglia, are an ideal platform to bridge the gap between traditional 
model systems and human biology [255-257]. The differentiation of fetal NPCs in 
vitro could be used to experimentally recapitulate brain development. Recent 
efforts intending to measure the transcriptome from the fetal human brain provide 
an unbiased in vivo standard using single-cell approaches and genome-wide 
transcriptome analyses [258, 259]. These studies suggest that fetal NPCs have a 
stronger genomic overlap with the in vivo cortex compared to iPSCs, allowing for 
the identification of specific neurodevelopmental processes related to 
pathophysiology of developmental disorders. 
3.8.2  Neuronal Progenitor Cells and Neuronal Differentiation 
Neuronal progenitor cells (NPCs) are at the forefront of preclinical studies for 
cellular therapy for brain disease [260-262]. There are a number of sources of 
neural precursors, including conditionally immortalized cell lines derived from fetal 
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tissue, neuronal stem cells derived from carcinomas, fetal neuronal stem cells, 
neuronal precursors isolated from the cortex after cerebral infarction, and 
precursors derived from embryonic or induced pluripotent stem cells [13, 57, 262-
271]. Most commonly, undifferentiated stem cells are treated with a neural 
induction protocol prior to transplantation to acquire lineage specificity and also to 
reduce the risk of tumorigenesis [13, 266, 272-274]. The retinoic acid (RA) 
differentiation protocol is the most frequently used for neuronal differentiation of 
mouse iPS or ES cells. Retinoic acid is a vitamin A derivative which plays a role in 
the specifying anterior-posterior development broadly across mammals. Anteriorly, 
RA promotes expression of master regulators such as the Hox genes which 
dictates developmental paradigms within the central nervous system [275].  RA 
interacts with cellular RA-binding proteins (CRABP), which then bind nuclear RA 
receptors to facilitate neuroectodermal differentiation [276]. Neural-specific 
transcription factors are expressed in iPSCS and ESCS following RA exposure 
[277]. Multiple cell types are produced using the RA differentiation method. 
Importantly, a small percentage of cells differentiate into glia [277]. The vast 
majority of cells derived from this method become mature neurons. Following the 
RA induction process, neurons express mature neuronal markers such as 
neuronal nuclei (NeuN), neurofilament, and type 3 tubulin, and are able to produce 
sodium, potassium, and calcium currents, and elicit spontaneous action potentials 
[278].  Both GABAergic and glutamatergic neurons are produced [277].  
3.8.3 Mechanisms of Cellular Therapy 
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Broadly speaking, the mechanisms of cellular therapy can be grouped into either 
cellular replacement or trophic support. However, it is difficult to separate these 
mechanisms in practice since many of the outcomes from either theoretical 
mechanism are often similar or the same. For example, transplanted NPCs may 
differentiate into functional neurons and replace those lost to stroke, and 
concurrently, also release factors which improve the synaptic plasticity of 
endogenous neurons in the vicinity to facilitate network recovery.  
Cellular replacement is an important mechanistic target for treatment of 
stroke and other focal brain lesions. In the case of NPC transplantation, neuronal 
replacement requires neuronal differentiation of NPCs and integration into the host 
neural circuitry. The former requisite, neuronal differentiation, is relatively easily 
achieved with the appropriate differentiation protocols [262, 279]. Some groups 
have carefully studied neural differentiation of transplanted cells. In one study, 
transplanted ESC-derived neural precursors differentiated into multiple neuronal 
subtypes, with the dominate subtype being GABAergic neurons (>50%), however, 
the proportion of glutamatergic neurons was not reported [280]. Following 3 
months after transplantation, only 25% of the remaining cells were NeuN+, while 
8% were positive for the astrocyte marker glial fibrillary acidic protein (GFAP), 
suggesting that both overall retention of cells is low, and that a significant 
proportion become astrocytes. Furthermore, continued proliferation after 
transplantation was also detected, but no tumor formation was noted at 1 and 3 
months after transplantation. In a separate study involving transplantation into the 
striatum following striatal stroke, 30% of transplanted cells were retained at 1 
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month, and the majority expressed neuronal markers [281, 282]. Very few 
expressed astrocyte or oligodendrocyte markers, and they did not report any 
proliferation following transplantation.  
The latter requisite for cellular replacement in stroke, integration into the 
host neural circuitry, is thought to be a major limitation of cellular replacement. 
Functional integration been reported by only a few groups. Neural progenitors have 
a greater ability to integrate if they differentiate into the appropriate phenotype [57]. 
Recently, a group described functional integration of transplanted NPCs using 
fluorometric calcium imaging and nerve tracing in a traumatic brain injury mouse 
model [56]. Other groups have described integration using immunohistochemistry 
techniques in various models, including in both healthy brains, PD, TBI, stroke, 
and others [18, 283-285]. More research is required to understand the extent of 
neuronal integration of NPCs following transplantation, and how it may be 
manipulated for network recovery.  
Trophic support is another major mechanism of cellular therapy. 
Transplanted cells can improve the survival, repair, and regeneration of 
surrounding tissue by providing factors which facilitate these recovery processes. 
Transplanted cells may act as vehicles for the sustained delivery of factors to 
promote regeneration [286]. Transplanted NPCs and other cell types release 
factors which can promote repair of the injured parenchyma following stroke [287-
289]. These trophic effects are both paracrine and autocrine [290-293]. A wide 
variety of released factors has been reported, including neurotrophins such as 
BDNF, GDNF, and NGF, vasculogenic proteins including VEGF, bFGF, and 
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immunomodulatory proteins such as the interleukins IL-10, IL-1, and CSF-1 [6, 32, 
292-296]. The secreted factors are thought to promote recovery via reduction of 
harmful inflammation and promotion of endogenous regenerative and reparative 
processes, including neurogenesis and angiogenesis [13, 260, 279, 297-301]. For 
some cellular therapies and in particular for BMSCs, trophic support is likely the 
major therapeutic mechanism. This is supported by experiments using BMSC 
conditioned media to treat the post-stroke brain, which led to similar levels of 
functional recovery compared to cellular treatments [292, 302]. 
3.8.4 Cell Transplantation Parameters and Strategies for Stroke 
A major goal of preclinical cell transplantation studies is to optimize the 
transplantation parameters to maximize their therapeutic efficacy. In terms of 
cellular therapy for ischemic stroke, the major parameters include administration 
route and timing of delivery; the optimal conditions likely depend on the cell type 
and animal model of cerebral infarction. The Stem Cell Therapy as an Emerging 
Paradigm for Stroke (STEPS) committee has determined guidelines for preclinical 
studies which should be accomplished prior to translating cellular therapy for 
human stroke patients [274]. The committee emphasized the need for a well-
characterized cell population, dose-response studies, and functional tests in at 
least two different models in two animal species [274].  
The specific pathophysiology of ischemic stroke creates challenges for 
directing cellular therapy to ischemic brain tissue. Following the cessation or 
reduction of blood supply to the brain parenchyma, cell death develops within 
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minutes (Chapter 3.3.5). The ionic gradients important for cellular membrane 
potential and neuronal signaling dilapidate and result in the release of toxic 
amounts of glutamate, which can reside in the tissue for days, and can interfere 
with transplanted cell survival and retention. Intracellular and released proteases 
are activated which accentuate cell death of native and transplanted cells, and also 
degrade the extracellular matrix, creating an environment inhospitable for cellular 
therapy. Inflammatory cells such as microglia/macrophages and monocytes 
infiltrate the hypoxic tissue and tend to exhibit a pro-inflammatory phenotype, 
which further antagonizes regenerative efforts (Chapter 3.3.4). The astrocytic 
barrier, which develops days to weeks after focal brain ischemia, may be inhibitory 
to axonal growth of both newly formed endogenous neurons and transplanted cells 
[29]. Strategies to overcome these limitations are necessary to advance preclinical 
efforts into therapeutics viable in human populations.  
Timing of cell transplantation is an essential parameter to be considered 
and can be optimized to overcome potential barriers to clinical translation. 
Transplantation timing has been performed at widely varying times after infarction 
(<1hr to months) but has rarely been compared directly. Early transplantation 
(hours-days) has shown some neuroprotective effects [281, 285, 303, 304], 
however, early time points are often avoided due to the widespread belief that the 
ongoing stroke pathology will interfere with transplant cell survival, and ultimately, 
transplant cell therapeutic efficacy. Our group and others perform transplantations 
around 7 days after stroke. At this point, the extracellular glutamate and edema 
have subsided, and regenerative activities are ramping up [305]. Transplantation 
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at this delayed timepoint may also be optimal since it allows for the augmentation 
of endogenous regeneration, which is thought to be the major therapeutic 
mechanism of transplanted cells for ischemic stroke. Treatment at a later timepoint 
may miss this window. It is also possible that repeated delivery may offer additional 
benefits, but this has also rarely been studied [296].  
Transplantation location is also a major consideration for cellular therapy 
for stroke. The most common and theoretically appealing strategy for cellular 
replacement for ischemic stroke is intracerebral transplantation. Many hypothesize 
that replacement of tissue in situ will facilitate greater recovery compared to 
treatment targeted elsewhere, however, this has very rarely been directly tested. 
Following degradation, the stroke core develops into a potential space where 
injections may be targeted with minimal compression of healthy brain tissue. 
However, transplantation into the cytotoxic stroke core results in massive cell 
death of transplanted cells, particularly in the setting of acute stroke [268, 289, 
306]. Previous studies have attempted to overcome or bypass some of these 
difficulties by either increasing the resiliency and efficacy of the transplanted cells 
(for example, by hypoxic preconditioning [23, 24, 31] or genetic manipulation [32]), 
or by transplanting in the peri-infarct region where the microenvironment is less 
hostile. Interestingly, one study tested the possibility of transplanting into the 
hemisphere contralateral to the stroke lesion, and not surprisingly, found greater 
transplant cell survival compared to injection into the lesion or intraventricular 
injection [271]. However, directing injections to healthy or peri-infarct regions 
requires invasive placement in sensitive brain tissue, which can be damaged 
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simply by delivery approach [33-35]. However, the extent of neuronal damage due 
to transplantation of cells or biomaterials is not well studied. Others have also 
tested intravascular and intranasal administration routes for cellular therapy with 
varying success [13]. Interestingly, many of these studies reported improvements 
in recovery despite low numbers of cells homing to the injury region, suggesting 
the therapeutic effects may be facilitated by released factors rather than cellular 
replacement [13]. Further research is needed to clarify the optimal time points and 
location targets for particular cellular therapies after stroke.  
The optimal number of cells needed to achieve therapeutic efficacy is also 
unknown. Previous studies have shown that intracranial transplantation of greater 
numbers of neural stem cells did not result in greater survival or neuronal 
differentiation [13, 281]. However, in a study that utilized an intravenous method 
of delivery, the improvements in behavioral deficits and infarct volume were dose-
dependent [303]. These discrepancies are not well understood, however, it is 
possible that first-pass circulation via the lungs and liver reduced the effective dose 
which reached the brain in the latter study [303]. Together, these studies suggest 
there is an upper limit in terms of therapeutic benefit. In our lab and others, we 
have demonstrated that transplantation of 200,000 cells into the peri-infarct region 
is safe and effective for the treatment of mini-strokes in mice [13, 268, 306, 307]. 
Future preclinical and clinical studies are necessary to determine the quantity of 
cells as a function of cell type, stroke size, and stroke location.  
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3.9  Biomaterials for Augmentation of Cellular Therapy for Ischemic Stroke 
3.9.1 Hydrogels as cell carriers for transplantation in stroke 
An alternative strategy to enhance cellular viability and effectiveness is to create a 
microenvironment in the stroke core favorable for transplantation and regeneration 
via hydrogel encapsulation [3, 11, 12, 36-39]. Hydrogels are biocompatible carrier 
materials that can be used to promote survival, differentiation, trophic potency, and 
functional integration of transplanted cells [11, 12, 27, 37, 39, 41]. Their ability to 
emulate the biophysical properties of soft neural tissue makes them ideal for 
engraftment into brain injuries [44-47]. Formulating hydrogels from extracellular 
matrix (ECM) components allows for reduced immunogenicity, preserves bio-
inductive properties, and allows for degradation by native mechanisms [308, 309]. 
Many tissue engineering studies in the stroke field have centered on hyaluronan 
(HA), which when used as a carrier for cellular therapy, can improve cell survival 
after transplant, promote angiogenesis and anti-inflammatory signaling, and 
encourage neuronal differentiation of stem cells [27, 33, 37, 41, 45]. However, low 
molecular weight HA is pro-inflammatory, and transplanting HA into the 
degradatory stroke core would carry an unnecessary risk of exacerbating 
inflammation [45]. Recently, a HA-based hydrogel was demonstrated to encourage 
vascular repair and neuronal migration to the stroke core in mice [49]. Released 
proteins such as growth factors play an integral role in regeneration, and ECM 
binding is a critical step of NPC mediated trophic support [4, 22, 27, 28, 53]. 
However, HA is an un-sulfated glycosaminoglycan which lacks the functional 
components necessary to enhance trophic factor retention and signaling. Other 
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brain ECM glycosaminoglycans may provide structural elements and functional 
microdomains that allow for sustained and endogenously regulated trophic 
signaling, which may improve regenerative potential. 
 A number of studies have investigated hydrogels as potential scaffolding for 
cellular therapy for the treatment of ischemic stroke. The hydrogel used, cell types 
implanted, stroke model studied, and main findings are summarized in Table 4.  
Table 4. List of studies of hydrogel encapsulation for cellular therapy in 
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3.10 Chondroitin Sulfate Glycosaminoglycans and Brain Regeneration 
Unlike HA, chondroitin-4-sulfate A (CS-A) possesses greater structural and 
functional elements to modulate trophic factor enrichment and promote 
autocrine/paracrine signaling [51, 52]. Endogenously, CS-A is an integral ECM 
constituent of the neural stem cell niche [47, 51-54]. ECM binding is a critical step 
of growth factor-mediated tissue repair [55]. CS is a multifunctional sulfated 
glycosaminoglycan implicated in regeneration and the response to brain injury. 
The sulfated elements of the CS disaccharide chains attached to native brain CS 
proteoglycans facilitate growth factor binding, retention, and presentation [47, 51, 
52]. The various roles of CS can be attributed to their sulfation patterns and 
pathobiological context. CS-A is involved in endogenous neural stem cell 
differentiation and migration, neurite/axon growth, and angiogenesis [315-321]. 
Other CS moieties such as CS-E and CS-C play a role in neuroprotection as part 
of the glial scar limits the spread of inflammation and necrotic debris following 
cerebral infarction [108, 322, 323]. The homeostatic deposition of these 
glycosaminoglycans in the peri-infarct region may also assist in regeneration [116, 
322, 323]. Previous studies have demonstrated that CS-A can support neural stem 
cells in vitro and transplanted cells in vivo following traumatic brain injury [53, 324]. 
Regenerative factors such as basic fibroblast growth factor (bFGF) and brain 
derived neurotrophic factor (BDNF), and the immunomodulatory protein interleukin 
10 (IL-10) have higher affinities for CS-A compared to HA [53, 325]. The secreted 
mitogen bFGF in particular plays an important role in brain repair after injury by 
promoting proliferation, migration, and survival of endothelial cells [326]. 
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Furthermore, bFGF also stimulates production of vascular endothelial growth 
factor (VEGF) which acts in conjunction with bFGF to promote angiogenesis [320, 
326]. Arteriogenesis and pial collateral vascular remodeling are also carried out by 
bFGF signaling after cerebral ischemia [176, 327, 328]. Our collaborators have 
recently shown that CS-A can improve growth factor and transplanted cell retention 
in a rat traumatic brain injury model, however, they are wholly unexplored as 
transplant mediums for the treatment of stroke [39, 53]. We hypothesize that these 
natural polymers can be used to create a depot in the stroke core for the growth 






4.1  Experimental design 
 
Figure 1. Overview of general experimental design. A) Treatment groups. B) 
Experimental timeline. 
4.1.1 Aim 1: Determine the effects of CS-A on NPC survival and differentiation. 
The limited survivability of transplanted cells in the ischemic brain is a significant 
barrier to clinical translation [3, 4, 37]. Sustained retention of transplanted cells is 
also necessary to effectuate recovery. Ensuring cell survival and creating a 
hospitable environment for prolonged retention will facilitate regeneration after 
transplantation and is a primary endpoint for CS-A encapsulation. Neuronal 
differentiation is desirable to achieve cellular replacement of neurons lost to stroke 
[9, 15, 284]. NPCs can differentiate become functional neurons that can integrate 
with host circuitry [16-20]. Previous studies have indicated that CS-A can promote 
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NPC proliferation and stemness, however, none have tested whether CS-A is 
amenable to neuronal differentiation for cellular therapy purposes [53]. Other 
groups have shown that CS with other sulfation patterns such as CS-E, may 
actually inhibit axonal growth in certain contexts such as spinal cord injury [47]. 
The ability of NPCs to differentiate into neurons with proper axon formation within 
CS-A in vitro and following transplantation into the stroke region is unknown. We 
hypothesized that CS-A encapsulation of NPCs will improve cellular retention and 
permit neuronal differentiation in vitro and in vivo following transplantation into the 
ischemic stroke core in mice.  
The effect of CS-A on NPC cell death and retention following transplantation 
was investigated using immunohistochemical (IHC) methods and ex vivo IVIS 
Spectrum imaging (Perkin Elmer, Waltham, MA) of brains transplanted with DiR 
(Thermo Fisher Scientific Life Sciences, Waltham, MA)-labelled cells following 
experimental endpoints. To test for acute transplant cell death, animals were 
sacrificed 3 days following transplantation of iPSC-derived NPCs with stable 
expression of GFP, and brains were isolated and sectioned. Transferase-mediated 
dUTP nick end labeling (TUNEL) and GFP co-staining were used to measure the 
number of dying transplanted cells. To measure cell retention, DiR-labeled NPCs 
were transplanted into the stroke core, and brains were isolated and imaged with 
the IVIS Spectrum imager. Cell retention was estimated using radiant efficiency. 
The total number of retained GFP-expressing transplanted cells were also counted 
2 weeks after transplantation into the stroke core. To determine whether CS-A can 
protect NPCs from low oxygen and glucose conditions, we performed oxygen and 
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glucose deprivation test using 0.1% oxygen for 3 hours in OGD media [186]. Media 
was collected and the lactose dehydrogenase (LDH) release assay was performed 
as a proxy for cell death. Protein was also collected, and the levels of the cell death 
and survival proteins cleaved caspase 3, BCL2, and HIF1 were measured and 
compared using Western blotting.   
In vitro and in vivo neural progenitor cell differentiation was studied using 
IHC and Western blotting techniques. For in vitro iPSC-NPC culture experiments, 
following completion of neurosphere induction, cells were either plated on a 
polystyrene culture dish coated with PDL-laminin, or loaded into the CS-A 
hydrogel, and maintained until the completion of the retinoic acid neural induction 
protocol (4 days without followed by 4 days with retinoic acid). The neuronal 
markers NeuN, SNAP25, TUJ1, GAD67, and NMDAR1b were measured and 
normalized to the housekeeping marker tubulin. Other markers, including non-
differentiated markers Nanog, SOX2, and Nestin, and the astrocyte marker GFAP, 
were also measured and compared. For in vivo differentiation experiments, the 
numbers and percentages of NeuN, GFAP, or SOX2 cells colabeled with GFP 
were counted in sections from brains isolated from animals 2 weeks after 
transplantation. Axon formation within the stroke core was determined using MAP2 
as an axonal marker, and GFAP as a marker for the glial scar, which demarcates 
the stroke core.  
Experimental design limitations: We initially chose 3 days post-transplantation to 
test the potential protective effects of CS-A for transplantation of NPCs into the 
ischemic core region based on previous studies of ischemic cell death [78, 120, 
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121, 132, 135]. However, it is possible that a small fraction of dead/dying cells may 
be cleared prior to this timepoint. Furthermore, the specific types of cell death were 
not studied. Transferase-mediated dUTP nick end labeling (TUNEL) staining can 
be used to count the number of cells with fragmented DNA, which canonically is 
implicated in apoptotic cell death. However, many cell death pathways are 
activated concurrently in ischemia, and it is possible that TUNEL staining does not 
cover a small proportion [131]. We chose to measure cell retention 2 weeks after 
transplantation since this time point matches our other experimental endpoints. 
Chronic (months) retention of transplanted cells was not tested and is a future point 
of study. Using DiR is beneficial in that it does not affect cell function, however, it 
is possible that it may not remain completed within the transplanted NPCs. 
Following cell death and phagocytosis, some DiR may be transferred to other cells.  
Furthermore, this technique does not have the spatial resolution to track individual 
cells or their intracranial distribution.  
While our lab and others have shown that iPSC-NPC derived neurons can 
produce spontaneous and evoked action potentials, we were unable to determine 
whether neurons differentiated in the CS-A hydrogel can as well [6]. Technical 
difficulties, in particular the failure of multiple experts to patch cells within the 3D 
hydrogel in vitro, was a major limitation to determine neuronal activity in vitro. For 
in vivo differentiation, we used immunohistochemical methods to determine 
transplanted cell differentiation phenotypes and axonal formation. However, this is 
insufficient to determine the possible neuronal function of transplanted cells, and 
whether they form viable connections with the host neural network. Finally, 
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transplantation into the stroke core may limit axonal formation, since they must first 
bypass the inhibitory astrocytic barrier. 
4.1.2 Aim 2: Determine the effects of treatment with CS-A encapsulated NPC on 
regeneration in the ischemic brain. 
The immune response plays a major role in the natural history of stroke 
pathophysiology and the response to transplanted materials [11, 27, 329, 330]. 
Microglia/macrophages are the major immune cells involved in stroke [103]. It is 
desirable for the hydrogel to either reduce harmful inflammation, remain immune-
inert, or promote a regenerative immune phenotype [41, 45]. The anti-inflammatory 
M2-type macrophage population is associated with neurogenesis, angiogenesis, 
and stroke recovery, while the M1 response is inhibitory to recovery and 
associated with infarct progression [103, 331]. Transplanted NPCs can dampen 
the immune response to facilitate recovery [7]. CS-A may augment this effect since 
it can enrich the anti-inflammatory factor IL-10 [53]. The astrocytic response is also 
important to nervous system repair [110, 323]. Following infarction, palisading 
astrocytes form a barrier separating the stroke core from healthy tissue to limit 
infarct extension, and likely limits the potential of cellular therapy directed to this 
region [323]. CS-A has been shown to reduce the astrocytic scar following 
traumatic brain injury, which may enhance cellular therapy [39]. 
We performed IHC analysis to test the astrocytic response to 
transplantation. Glial scar width and the intensity of GFAP staining in the peri-
infarct region 2 weeks after treatment. To study the immune response to CS-A 
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encapsulation, we performed immunohistochemical and protein assays, including 
protein multiplex (Meso Scale Diagnostics, Rockville, MD) assays and Western 
blotting analysis from both in vivo tissue samples and primary stroke core 
macrophage cultures in vitro. IHC was used to detect the number of PPAR 
expressing macrophage/microglia. PPARγ is a marker for the M2 subset of 
macrophages, which express pro-regenerative molecules to facilitate tissue repair 
[102, 103, 107, 206, 330]. The protein expression levels of IBA1 and IL10 were 
also measured using Western blotting. A protein array was used to quantitatively 
measure the levels of inflammatory related proteins monocyte chemoattractant 
protein 1 (MCP-1), macrophage inflammatory protein 1a and 1b (MIP-1a, MIP-1b), 
tumor necrosis factor (TNF), and interluekins 4 and 6 (IL-4, IL-6) using tissue 
isolated from both the stroke core and peri-infarct regions across treatment groups. 
To study the potential effects of CS-A on macrophage phenotype, stroke core 
macrophages were isolated from mice 3 days after infarction, dissociated, and 
plated onto 6 well polystyrene culture dishes or into CS-A hydrogel. Following 3 
days of in vitro culture, the markers VEGFR2, TIE2, PPAR, bFGF, and IL10 were 
measured using Western blotting. In some experiments, neutralizing IL10 antibody 
was added to the culture media to determine the significance of IL10 on CS-A-
mediated macrophage polarization.   
The innate capability of the adult brain to create new neurons is inadequate 
to facilitate meaningful recovery after stroke. Formation of new neurovascular units 
is paramount to reestablishment of neuronal circuitry lost to infarction [332]. 
Intracranially transplanted NPCs provide trophic support to the surrounding tissue 
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via the production and release of regenerative factors [6, 7, 9]. Neovascularization 
in the hypoxic stroke region is necessary for the survival and success of both 
endogenously formed newborn neurons and transplanted NPCs and is also 
prognostic of recovery [176]. The interaction of released growth factors with 
surrounding ECM is a critical step of trophic support and growth factor mediated 
regenerative activities [28, 55, 333]. Following ischemic damage, the ECM is 
extensively degraded and is unable to fully support trophic enrichment offered by 
transplanted NPCs [37, 41, 57, 334]. CS-A is an ECM component of the 
endogenous neural stem cell niche and can bind, partition, and orchestrate 
signaling of BDNF, bFGF, IL10, and other released factors important for healing 
[39, 53]. These factors can promote endogenous neurogenesis and 
angiogenesis/arteriogenesis to facilitate recovery [5, 6, 9, 22, 36, 335]. We 
hypothesized that the combination of CS-A and NPCs may synergize to enhance 
the formation of new neurovascular units.  
To measure neurogenesis and angiogenesis following transplantation of 
CS-A encapsulated NPCs, animals were injected with BrdU daily after treatment, 
which labels newly formed cells. Glut1 and NeuN co-labeling with BrdU was used 
to measure the formation of newly formed endothelial and neuronal cells, 
respectively. DCX staining was used to label migrating neuroblasts, a fraction of 
which contribute to neurogenesis after stroke [111, 180, 186, 305, 336]. The 
number of Glut1+ microvessels in the stroke core region was also counted. 
Angiogenic signaling was detected in the stroke core region using Western blotting 
for bFGF, p-STAT3, p-AKT, and VEGF. Endothelial migration also contributes to 
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the formation of new vasculature [178, 206, 208, 337]. Endothelial haptotaxis was 
tested using a hydrogel preference microfluidic device designed by our 
collaborators [338]. NPC-conditioned medium was used to promote haptotaxis 
towards a well, and brain endothelial cells (B.end3) migrated through either 
hyaluronan or CS-A hydrogel towards the well. The number of cells in each type 
of hydrogel was counted after 24 hours. The effects of endothelial division were 
also tested using Western blotting for the cell division marker Cyclin D1.  
Experimental design limitations: Neurologic recovery can occur via multiple 
mechanisms. Neurogenesis is among the most hopeful since it can reproduce 
neuronal tissue lost to infarction. However, the rates of native endogenous, even 
after they are amplified in response to ischemic insult, are very low and are 
insufficient for functional recovery [111, 180, 335, 339, 340]. Post-stroke 
neurogenesis peaks at 3-4 weeks after stroke [187, 305, 341]. It is possible that 
the time timepoint selected for monitoring DCX migration and formation of newborn 
neurons (2 weeks post-treatment, 3 weeks post-stroke) may not capture peak 
neurogenic activities potentially affected by treatment. Other recovery 
mechanisms, such as altered synaptic plasticity and cortical remapping may also 
be affected by treatment, however, they cannot be easily measured using IHC 
methodology [342]. Future studies may take these alternate mechanisms into 
account.  
4.1.3 Aim 3: Determine the effects of treatment with CS-A encapsulated NPCs on 
local blood flow restoration and functional recovery after ischemic stroke.  
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Blood flow recovery is essential to functional recovery after stroke and for 
sustained support of transplanted cells [22]. Pial collaterals are a primary regulator 
of blood flow to the ischemic area and their recruitment is prognostic of recovery 
[176]. Restoring function is the ultimate goal of treatment. Stroke directed to the 
sensorimotor barrel cortex in mice results in loss of whisker and forelimb sensation 
and deficits in both general and forelimb motor function [215, 343, 344]. 
Furthermore, post-stroke neuropsychiatric deficits have also been reported in 
rodents. Mice suffering from cortical stroke develop behavioral abnormalities such 
as apathy, anhedonia, and anxiety-like behaviors [345]. We hypothesized that 
treatment with CS-A encapsulated NPCs would improve their ability to promote 
blood flow and behavioral recovery. Furthermore, given that CS-A is known to 
enrich bFGF in vitro and in vivo following transplantation into the post-TBI brain, 
we hypothesized that bFGF may facilitate vascular regeneration and blood flow 
recovery [39, 47, 53].   
To test blood flow recovery, we utilized laser Doppler flowmetry to estimate 
cortical perfusion of the ischemic hemisphere [186]. Cortical blood flow was 
measured before and weekly after stroke. To measure collateralization, we used 
genetically modified mice expressing alpha smooth muscle actin tagged with GFP 
(SMA-GFP) to visualize muscular vessel dynamics in the pial layer of the 
meninges. Following the conclusion of the experiment, SMA-GFP mouse brains 
were imaged, and the numbers and widths of the pial collateral arteries were 
measured. Immunohistochemistry was used to verify alterations in pial vessel 
diameter were due to outward remodeling. 
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The stroke model used in the Wei lab is targeted to the right sensorimotor 
cortex which results in left whisker and left forepaw sensory and motor deficits 
[124, 215]. Sensorimotor behavioral recovery was tested using the rotarod, 
adhesive removal, corner, and pull tests [186, 262, 264, 306, 346]. The rotarod 
test assesses general motor coordination and balance. The adhesive removal test 
assesses the ability of the mouse to sense and remove a sticker from their affected 
(left) forepaw. The corner test assesses the whisker function of mice after they 
enter a corner in a behavior arena. The isometric volitional pull test assesses paw 
and forelimb strength. To screen for post-stroke neuropsychiatric deficits, we used 
the open field test and the tail suspension test. The open field test assesses anxiety 
as a function of the time spent in the center 25% of the arena. An added benefit of 
the open field test is that sensorimotor-related data, such as travel distance and 
velocity, can also be gleaned from the analysis as secondary outcomes. The tail 
suspension test assesses apathy to the stress of being suspended by the tail 
upside down.  
Experimental design limitations: Mice suffering from mini-strokes to the 
sensorimotor cortex incur well-defined deficits that can be readily tested using the 
behavior tests described above. However, the auto-recovery rate is high due to the 
relatively small size of the infarction, and also due to the resiliency and plasticity 
of the mouse brain. In our model, a large proportion animals exhibit behavior that 
is similar to pre-stroke (uninjured) levels by 3-4 weeks after surgically-induced 
infarction. This can be reduced by removing animals that showed weak behavioral 
phenotypes prior to randomization and treatment, however, it is possible that the 
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experimental design is underpowered to test differences between treatment 
groups at delayed timepoints (i.e. 3 weeks after stroke). Future studies using more 
severe infarct models or increased numbers may be necessary to elucidate 
potential differences at delayed timepoints after treatment.  
4.2  Procedures 
4.2.1 Mouse stroke model, laser Doppler flowmetry, and transplantations 
All animal procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) at Emory University and are in accordance with the NIH and 
Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines. The 
mouse stroke model was performed as previously described using C57BL/6 mice 
(8-12 weeks) from Jackson Laboratories [347]. Briefly, under anesthesia, the right 
middle cerebral artery was permanently ligated using a 10-0 suture (Surgical 
Specialties Co., Reading, PA), accompanied by bilateral common carotid artery 
ligation for 7 min. Laser Doppler flowmetry was performed as previously described 
[186]. Briefly, incisions were made under anesthesia to expose the skull above the 
right MCA territory, and the Periscan Laser Doppler perfusion imaging (LDPI) 
system was used to scan a 3x3 mm square area with a center point of medial–
lateral (ML) +4.1 mm, and six edges of the infarct area: ML +2.9 mm, ML +5.3 mm, 
anterior-posterior (AP) -1.5 mm, and AP +2.0 mm, respectively. The LDPI software 
(Perimed, Stockholm, Sweden) was used to analyze perfusion. Seven days after 
stroke surgery, mice skulls were thinned over the visible region of the stroke core, 
and 200,000 cells suspended in 2 μl SATO or 200,000 cells loaded into 2 μl CS-A 
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hydrogel, or 2 μl CS-A hydrogel with medium only were loaded into a Hamilton 
syringe (Hamilton, Reno, NV, USA) and injected at a depth of 1mm from the skull. 
This number and volume of cells was shown to be safe and effective in our 
published studies. Effort was taken to avoid damaging arteries and veins during 
transplantations; animals with detectable vascular damage were excluded from the 
study.  
 This mouse sensorimotor cortex mini-stroke model was selected for its 
defined and highly reproducible cortical infarct and significant generation of a 
regenerative peri-infarct region. The survival rate for this surgery compared to the 
MCAo is very high (>95%).  Male mice were selected to reduce the potential 
neuroprotective effects of estrogen, which may also affect regenerative capacity 
after stroke. Adult mice were selected to reduce potential confounding effects of 
brain maturation in neonatal mice, and also to avoid the high mortality rates in aged 
mice after cerebral infarction surgeries. The stroke core was targeted as the 
transplantation site since it is a potential space for injections and is preferable to 
damaging the viable regenerative penumbra.  
4.2.2 Neural progenitor cell culture and CS-A hydrogel preparation 
Mouse induced pluripotent stem cell–derived neural progenitor cells (iPSC-NPCs) 
were differentiated from iPSCs originally generated from mouse embryonic 
fibroblasts (Stemgent Inc., Cambridge, MA) as previously described [32]. This line 
of iPSC-NPCs expresses GFP to permit tracking following transplantation. iPSCs 
were cultured in the N2B27 serum free medium at 20% O2, 5% CO2, at 37° C. 
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The medium was prepared with 45% Dulbecco’s modified eagle medium: nutrient 
mixture F-12 (DMEM/F12; Sigma Aldrich, St Louis, MO), 45% Neurobasal (Thermo 
Fisher Scientific, ), 0.5% N2 supplement (Thermo Fisher Scientific), 1% B27 
supplement (Thermo Fisher Scientific), 1% GlutaMAX, 1% nonessential amino 
acids (Sigma Aldrich), 0.1 mM β-mercaptoethanol (β-ME; Sigma Aldrich), 100 
U/mL penicillin/streptomycin (Sigma Aldrich), 5% knockout serum replacement 
(KSR; Thermo Fisher Scientific). The small molecules were recombinant leukemia 
inhibitory factor (LIF; 10 ng/mL; Millipore, Billerica, MA), CHIR 99021 (3 µM; 
Tocris), (S)-(+)-Dimethindene maleate (2 µM; Tocris) and minocycline 
hydrochloride (2 µM; Santa Cruz Biotechnology, Santa Cruz, CA)37. Before 
differentiation, the iPSCs were cultured in DMEM (Sigma Aldrich), 10% ES-FBS 
(Thermo Fisher Scientific), GlutaMAX, nonessential amino acids, nucleoside mix, 
LIF, β-ME (Sigma Aldrich), LIF, b-ME, and penicillin/streptomycin. All cells used in 
this study were harvested and ready for transplantation after an established ‘4−/4+’ 
retinoic acid (RA, 1 μM; Sigma Aldrich) neural differentiation protocol. Chondroitin 
sulfate hydrogel was prepared as previously described [53]. Lyophilized 
chondroitin sulfate glycosaminoglycan hydrogel (5% w/v) was reconstituted with 
SATO medium or cell suspension (100,000 cells/uL), then loaded into the Hamilton 
syringe for injection. For bFGF-neutralizing antibody experiments, 2.5ug/mL 
antibody (Millipore, Billerica, MA) was added to the cell suspension prior to 
reconstitution of the lyophilized hydrogel. For in vitro iPSC-NPC culture 
experiments, following completion of the RA differentiation protocol, cells were 
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either plated on a polystyrene culture dish coated with PDL-laminin, or loaded into 
the CS-A hydrogel, and maintained for 7 days. 
 
4.2.3 Cell retention imaging 
Cells were labeled with DiR (1,1'-Dioctadecyl-3,3,3',3'-
Tetramethylindotricarbocyanine Iodide) (Thermo Fisher Scientific Life Sciences, 
Waltham, MA) per manufacturer’s protocol immediately prior to transplantation. 
Following conclusion of the in vivo experiments, brains were isolated and imaged 
with the IVIS Spectrum imager (Perkin Elmer, Waltham, MA). Cell retention was 
estimated using radiant efficiency.  
4.2.4 Oxygen and glucose deprivation (OGD) conditions and lactate 
dehydrogenase (LDH) cytotoxicity assay 
Cells were maintained in a neurobasal media with B-27 serum-free culture 
supplement and L-glutamine (Invitrogen, Carlsbad, CA) until time of 
experimentation. Media was exchanged for a physiological buffer solution lacking 
glucose (120 mM NaCl, 25 mM Tris-HCl, 5.4 mM KCl, 1.8 mM CaCl2, pH to 7.4 
with NaOH). Cells were then incubated in a calibrated hypoxia chamber perfused 
with 5% CO2 and balanced nitrogen for a final ambient oxygen level of 0.2% for 
3 hours. Oxygen level was established, maintained, and monitored by the ProOx 
360 sensor (Biospherix, NY). After 3 hours, cells were returned to the normal 
incubator and the existing OGD media was completely changed out into normal 
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oxygenated complete neuronal culture media for 24 hours. At 24 hours after OGD, 
media was collected for the lactate dehydrogenase (LDH) cytotoxicity colorimetric 
assay (Sigma). The LDH assay was performed according to the manufacturer’s 
protocols.  
4.2.5 Immunohistochemistry and image analysis 
Animals were sacrificed by decapitation and brains were immediately removed and 
immersion fixed in 10% buffered formalin for 72 hours, then dehydrated in 30% 
sucrose, then mounted and sliced using a cryostat into 10 μm thick coronal 
sections (Leica Microsystems, Buffalo Grove, IL). Stereology was carried out as 
previous described. For systematic random sampling in design-based 
stereological counting, every 10th (90 µm apart) brain section across the entire 
region of interest were counted. For multi-stage random sampling, six fields per 
brain section were randomly chosen under 10, 20×, or 40× magnification of an 
epifluorescent microscope or in confocal images. The sections were air dried and 
fixed with 10% buffered formalin (Fisher Scientific, Pittsburgh, PA, USA). Brain 
sections were then submerged in an ethanol/acetic acid solution (2:1) for 10 min, 
washed 3 times with 1x PBS solution, and incubated with 0.2% Triton X-100 for 45 
min. Slides were then blocked with 1 % fish gelatin (diluted in PBS; MilliporeSigma) 
for 1 hr at room temperature. Slides were incubated with, rabbit anti-Glut-1 (1:400) 
and goat anti-SMA (1:400, Santa Cruz Biotechnology, Dallas, TX, USA), chicken-
anti-GFP (1:300, Abcam) and mouse anti-NeuN (1:400, MilliporeSigma), or mouse 
anti-MAP2 (1:200, MilliporeSigma) primary antibodies diluted in PBS at 4°C 
overnight. For double-staining of slides with BrdU, brain sections were post-fixed 
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with formalin in 10% buffered formalin and washed in PBS. Slides were then 
treated with methanol (-20°C) and allowed to air dry. After rewetting in PBS, 
sections were treated with 0.1 mL borate buffer (pH 8.4). Slides were then 
incubated with rat anti-BrdU (1:400; ABD Serotec, Raleigh, NC) overnight at 4°C. 
Primary antibodies were washed with PBS and replaced with secondary antibodies 
Alexa Fluor488 goat anti-mouse (1:300; Life Technologies, Grand Island, NY), and 
Cy3-conjugated donkey anti-rat (1:300; Jackson ImmunoResearch Laboratories, 
West Grove, PA) for 1 hr at room temperature before rinsing with PBS. After a final 
PBS wash, slides were mounted with Vectashield fluorescent mounting medium 
(Vector Laboratory, Burlingame, CA), and cover-slipped for microscopy and image 
analysis. Blinded stereological counting was performed on 6 randomly chosen 
microscope images of the stroke core region per section, and 6-8 sections were 
analyzed per animal. The number of microvessels (Glut1) within the stroke core, 
and the number of Glut1/BrdU colabeled endothelial cells within the core and the 
peri-infarct area were counted. The number of GFP and NeuN co-labelled cells 
were counted.  
4.2.6 Pial vessel imaging and analysis 
Two weeks after transplantation experiments, smooth muscle actin-GFP animals 
from Jackson Laboratories were sacrificed by decapitation and brains were 
immediately removed and imaged (1.25x and 4x) using an Olympus BX61 upright 
epifluorescent microscope (Olympus, Center Valley, PA, USA). Whole hemisphere 
images were reconstructed using Adobe Photoshop CS6 (Adobe Inc., San Jose, 
CA, USA).  For each MCA pial collateral artery, diameters were measured using 
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ImageJ (NIH) at 6-10 locations along the anastomoses and then averaged. A 
recruited collateral was defined as having a diameter greater than 25% than the 
average collateral in the non-injured (sham surgery) mouse. Only anastomoses 
with explicit and discernable origins were measured. 
4.2.7 Western blot analysis 
The infarct core region was homogenized using Mammalian Protein Extraction 
Reagent (M-PER) Lysis buffer with phosphatase and proteinase inhibitors (Pierce, 
Rockford, IL). Tissue samples were centrifuged and the supernatant was isolated. 
Protein concentration was determined using the Bicinchoninic Acid Assay (Sigma 
Aldrich, St. Louis, MO). Protein samples were loaded into 12% polyacrylamide gels 
and separated via sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) in a Hoefer Mini-Gel system (Amersham Bioscience, Piscataway, 
NJ). Protein was then transferred onto a polyvinylidene fluoride (PVDF) membrane 
(BioRad, Hercules, CA). Membranes were blocked using 5% BSA diluted with TBS 
and 0.05% Tween 20  (TBST) at room temperature for 1 hour, then incubated 
overnight with primary antibodies for bFGF (1:500, Cell Signaling, Danvers, MA, 
USA), p-STAT3 (1:1000, Cell Signaling, Danvers, MA, USA), p-AKT (1:1000, Cell 
Signaling, Danvers, MA, USA), VEGF (1:1000, Cell Signaling, Danvers, MA, USA), 
and the loading control Tubulin (1:5000, Sigma-Aldrich, St. Louis, MO After 
washing with TBST, membranes were incubated with AP-conjugated secondary 
antibodies (GE Healthcare, Piscataway, NJ) for 1 hour, then washed with TBST, 
and exposed to bromochloroidolylphosphate/nitroblue tetrazolium. Signal intensity 
was quantified using ImageJ (NIH) and normalized to tubulin intensity.  
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4.2.8 Hydrogel haptotaxis assay 
Microfluidic devices were fabricated as previously described [338]. Briefly, side 
channels composed of CS-A or HA hydrogel surrounding a central channel where 
10,000 mouse brain endothelial cells (bEnd.3, ATCC, Manassas, VA, USA) pre-
labelled with Hoechst were loaded with either SATO medium or NPC conditioned 
medium. Following 24 hours, devices were imaged and the number of cells within 
each hydrogel were counted. The experiment was repeated in triplicate.  
4.2.9 Primary stroke core macrophage isolation and culture 
Mice were subjected to stroke surgeries as discussed in 4.2.1: Mouse stroke 
model, laser Doppler flowmetry, and transplantations. 3 days and 7 days after 
stroke, the visible infarct core regions from the mice were carefully dissected, 
pooled, and then dissociated in trypsin + EDTA. The pooled tissue suspension was 
centrifuged, washed with PBS, and resuspended with DMEM + 10% FBS and 
plated on polystyrene tissue culture plates or into CS-A hydrogel. Following culture 
overnight, non-adherent cells and stroke core debris were removed, and the media 
was replaced. For the IL-10 neutralization experiments, 1ug/uL anti-IL-10 antibody 
(R&D Systems, MAB417) was added to the cell culture media.  
4.2.10 U-PLEX (Protein Multiplex) 
The U-PLEX Assay platform was purchased from Meso Scale Diagnostics (MSD, 
Rockville, MD, USA) and used according to the manufacturer’s protocol. Sample 
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preparations and measurements were performed by the Emory Multiplexed 
Immunoassay Core (EMIC).  
 
 
4.2.11 Sensorimotor behaviour analysis 
For all behavior tests, mice were tested prior to stroke surgeries, 1 week after 
stroke, and 1-2 weeks after treatment. The corner and adhesive removal tests 
were carried out as previously described [186]. The corner test gauges rodent 
whisker function. For the corner test, mice were placed in a star-shaped chamber 
with each corner forming a 30° angle and allowed to roam freely for 15 minutes. 
Animal activity was recorded with an overhead camera, and at a later timepoint, a 
blinded investigator observed and counted instances where the mouse entered the 
corner, reared up, and turned either right or left. The adhesive removal test is used 
to monitor mouse motor and sensation of the forelimb. For the adhesive removal 
test, a small adhesive was placed on the mouse forepaw and the time for the 
animal to remove the adhesive was recorded. Animals were trained for 3 days prior 
to stroke surgery and all tests were carried out by a blinded investigator. The pull 
test was used to monitor mouse forelimb strength. The automated isometric 
volitional pull test was performed and analyzed using MotoTrak software (Vulintus, 
Dallas, TX, USA) as previously described [348]. Briefly, mice were trained over 2 
weeks to pull a lever of their own volition. Following training, a force threshold of 
30g was set; a ‘hit’ was defined as >30g of pull force. The mice were placed in the 
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pull test chamber for 1 hour and pull force and number of pull attempts were 
recorded by the MotoTrak software. Hit rate is defined as the fraction of successful 
pulls (>30g), and mean attempt force is defined as the average force used for each 
attempt.  
4.2.12 Statistics 
Data were expressed as the means +/- SEM. GraphPad Prism 6 (GraphPad 
Software, San Diego, CA) was used for statistical analysis and graphic 
presentation. Calculated power analysis based on the variance and effect size in 
preliminary blood flow studies were used estimate a sample size of n=9 for 95% 
power in a 1-way ANOVA; to account for potential unforeseen increases in 
variation we extended the group size to n=12.   
4.2.13 Randomization and blinding 
All animals were assigned a number and box label and randomly assigned to 
treatment groups evenly. All researchers performing stroke surgeries, injections, 
blood flow measurements, in vivo imaging, microscopy, histological analysis, and 
data analysis were blinded to the treatment groups until collection and analyses 
were completed.   
4.2.14 Chemicals and reagents 
Unless otherwise explicitly stated, all chemicals and reagents were purchased 




5.1  Aim 1: Determine the effects of CS-A on NPC survival and differentiation. 
5.1.1 CS-A encapsulation reduces cell death of transplanted NPCs  
Mouse induced pluripotent stem cells underwent the 4-/4+ retinoic acid 
differentiation protocol which produces neuronal lineage committed NPCs. NPCs 
were transplanted into the ischemic stroke core in mice 7 days after infarction 
either encapsulated with CS-A (CS-A + NPC) or directly without encapsulation 
(NPC). 200,000 NPCs tagged with GFP in 2ul were transplanted. Following 3 days, 
mice were sacrificed, their brains were isolated and sectioned, and stained for GFP 
and TUNEL, a marker of cell death (Figure 2 A). The proportion of TUNEL+/GFP+ 
cells in the stroke core region was compared. The percentage of transplanted NPC 
cell death was found to be significantly reduced in the CS-A encapsulated group.  
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Figure 2. Encapsulation with CS-A reduces NPC cell death following 3 days 
after transplantation into the ischemic core. NPCs were transplanted with or 
without CS-A encapsulation into the ischemic stroke core 3 days after 
surgically induced infarction. A) Representative images of TUNEL staining 
Arrows indicate TUNEL/GFP co-stained cells. B) Analysis of transplant cell 
death. n=4 and 6/group. * indicates p<0.05; two-tailed T-test. 
We next tested whether CS-A may provide neuroprotection in an in vitro oxygen 
and glucose deprivation (OGD) experiment. Neuronal lineage committed NPCs 
were either encapsulated in CS-A or non-encapsulated, then exposed to OGD 
conditions (0.1% oxygen, 5% CO2) for 6 hours. Following exposure to OGD, cells 
were ‘reperfused’ with fresh media for 24 hours. After this, media was collected for 
lactose dehydrogenase (LDH) assay, which reflects the extracellular release of 
lactose dehydrogenase which is an intracellular enzyme. Increased LDH activity 
reflects increased cell death [121-123, 129, 130, 185]. We also tested whether 
bFGF may play a neuroprotective role to OGD insult by co-administering a 
neutralizing antibody to bFGF during OGD and reperfusion. We found that LDH 
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release correlated to ~50% cytotoxicity in all groups compared to the full kill 
positive control (Figure 3 A). There was no difference between treatment groups 
or those exposed to neutralizing bFGF antibodies. Cells were isolated for protein 
collection, and levels of cleaved caspase 3, BCL2, and HIF1 were compared 
(Figure 3 B). Correspondingly to the LDH release results, we found no differences 
between these protein levels.  
 
Figure 3. LDH release following oxygen and glucose deprivation (OGD). 
Media was collected from NPCs exposed to hypoxic conditions (Oxygen and 
glucose deprivation (OGD) conditions and lactate dehydrogenase (LDH) 
cytotoxicity assay). A) Analysis of LDH release between treatment groups. 
B) Analysis of protein levels of cleaved caspase 3, BCL2, and HIF1 between 
treatment groups. n=3/group. * indicates p<0.05; One-way ANOVA with 
Bonferroni correction for A) and two-tailed T-test for B).  
5.1.2 CS-A encapsulation improves NPC retention following transplantation 
We next tested the capabilities of CS-A to promote transplanted cellular retention. 
Intracranial transplantations (2 µL, 100k cells/ µL) were performed into the stroke 
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core region 7d after stroke and animals were sacrificed 14d after transplantation. 
Significantly more transplanted cells were detectable 2 weeks after transplantation 
in the CS-A encapsulation group as detected by ex vivo fluorescent imaging and 
also immunohistochemical cell tracking (Figure 4).  
 
Figure 4. CS-A encapsulation improves NPC retention 14 days after 
transplantation. NPCs were transplanted intracranially with or without CS-A 
encapsulation and sacrificed 2 weeks later. A) Representative images of 
radiant efficiency heatmaps 2 weeks after transplantation of DiR-labelled 
cells (Cell retention imaging). B) Analysis of DiR fluorescence. n=4-5/group. 
C) Representative fluorescent images of transplanted GFP+ cells in the 
stroke core. D) Analysis of cell retention. n=6/group. E) Representative 
images of transplanted CS-A encapsulated cells at 10x (top) and 40x 
(bottom) 2 weeks after transplantation. * and ** indicates p<0.05 and p<0.005, 
respectively; two-tailed T-test.   
5.1.3 Characterization of NPC differentiation in vitro following CS-A 
encapsulation 
Whether and to what degree CS-A can facilitate neuronal differentiation of NPCs 
under the retinoic acid (RA) differentiation protocol is unknown. To test the 
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possibility of neuronal differentiation, we encapsulated IPSC-derived 
neurospheres into CS-A and exposed them to the RA 4-/4+ neural lineage 
commitment protocol as previously described (Figure 5) [6]. 
 
Figure 5. Overview of in vitro differentiation experiments. Mouse iPSCs were 
induced into neurospheres using rotary culture then underwent the RA 
neural induction protocol (Neural progenitor cell culture and CS-A hydrogel 
preparation).  
NPCs grown in vitro in the CS-A hydrogel expressed the same levels of 
neuronal markers, including the mature neuron marker NeuN, the pre-synaptic 
marker SNAP25, and the axonal/dendrite markers MAP2 and TUJ1 as NPCs 
grown on traditional PDL-laminin coated polystyrene plates. Furthermore, we also 
found similar levels of expression of GAD67, a GABAergic neuron marker, and 
NMDAR, a glutamatergic marker in the CS-A group compared to the non-
encapsulated group. The cells within the hydrogel also appeared to have neuronal 
morphology following MAP2 immunostaining. This suggests NPCs grown with CS-
A can differentiate into multiple neuronal types and show similar growth of axons 
and synapses compared to non-encapsulated differentiation on PDL-laminin 
coated polystyrene plates. Together, these results suggest that CS-A does not 
affect neuronal differentiation.  
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Figure 6. Neuronal differentiation of CS-A encapsulated NPCs. A. 
Representative Western blotting and analysis for NeuN, SNAP25, TUJ1, 
GAD67, and NMDAR1b. B. Representative image of MAP2 staining of 
differentiated NPC within CS-A. n=4/group. * p<0.05, two-tailed T-test.  
Next, we tested whether CS-A encapsulation may affect differentiation into non-
neuronal cell types, including astrocytic differentiation or non-differentiation. 
Markers including Nanog, Sox2, Nestin, and GFAP were used to distinguish 
astrocytic and non-differentiated cells (Table 5).  





 iPSCs NPCs Astrocytes Neurons 
Nanog High Low None None 
Sox2 High High Low None 
Nestin Low High Low Low 
GFAP None Low High None 
NeuN None Low None High 
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Using Western blotting, we found that Nanog and Sox2 levels were both expressed 
at very low levels in either culture condition. However, Nanog was significantly 
reduced by CS-A encapsulation. This indicates that CS-A may reduce the 
proportion of iPS cells which fail to differentiate following the RA differentiation 
protocol in vitro. The levels of Nestin and GFAP were similar, suggesting that non-
differentiated NPCs and astrocytic differentiation was not affected by CS-A 
encapsulation. Taken together, these results suggest that in vitro differentiation of 
NPCs is largely unaffected by CS-A encapsulation.  
 
Figure 7. Protein expression of non-differentiated and glial markers of CS-A 
encapsulated NPCs. A) Representative Western blotting of Nanog, Sox2, 
Nestin, and GFAP. B) Analysis of Western blotting. n=4/group. * p<0.05, two-
tailed T-test. 
5.1.4 Characterization of NPC differentiation in vivo following transplantation 
Following tests for differentiation in vitro, we next studied differentiation of cells 
transplanted into the infarct core region 7 days after infarction. Neuronal 
differentiation of transplanted cells allows for the possibility of replacing neurons 
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lost to cerebral ischemia. Two weeks after transplantation, the number of NeuN 
and GFP colabeled cells were compared between CS-A encapsulated and non-
encapsulated treatment groups using IHC. In line with the in vitro differentiation 
studies, CS-A did not alter the proportion of neuronal differentiation (Figure 8 A-
B). Approximately 60-65% of transplanted cells were NeuN+, indicating a large 
proportion of neuronal differentiation. However, the total number of differentiated 
neurons was nearly 3 times in the CS-A encapsulation group compared to the non-
encapsulated NPC treatment group (Figure 8 B). This is likely due to the increased 
cellular retention.  
 
Figure 8. Neuronal differentiation of NPCs 14 days after transplantation. A) 
Representative images of NeuN+ and GFP+ colabeled cells in the infarct core 
2 weeks after transplantation. B) Analysis of percentage and number of 
NeuN/GFP colabeled cells. n=6-8/group. * indicates p<0.05; two-tailed T-test. 
The proportion of non- and astrocytic differentiation were also measured using IHC 
methods. Glial differentiation was determined using GFAP/GFP co-labelling, and 
non-differentiation was determined with Sox2/GFP co-labelling (Figure 9 A). 
Following 14 days after transplantation, the proportion of astrocytic differentiation 
of NPCs was significantly reduced by CS-A encapsulation (Figure 9 B). 
 83 
Interestingly, we also noted that many of the non-encapsulated cells which 
transplanted into GFAP+ astrocytes appeared to integrate into the astrocytic 
barrier. While very low, the proportion of non-differentiation of NPCs was 
significantly increased by CS-A encapsulation (Figure 9 B).  This is contrary to the 
in vitro finding that CS-A reduces expression of Nanog, a marker of non-
differentiation (Figure 7). Together, these results suggest that CS-A encapsulation 
permits similar neuronal differentiation of NPCs, reduces astrocytic differentiation 
of transplanted cells, and increased the proportion of non-differentiated cells. 
Furthermore, CS-A increases cellular retention of transplanted cells, leading to an 
increased number (but not percentage) of differentiated neurons. This allows for 
the possibility of neuronal replacement.   
The finding that CS-A may promote stemness of NPCs following 
transplantation is supported by similar work by our collaborators [39]. In their 
treatment scheme, neural stem cells are isolated from SVZ are encapsulated in 
CS-A and transplanted without any type of differentiation intervention. This 
suggests that CS-A may promote stemness in the absence of factors which 
promote differentiation, i.e. the retinoic acid differentiation protocol we employ to 
encourage neuronal differentiation prior to transplantation. Therefore, one possible 
explanation for the increased proportion of non-differentiated cells in this work may 
be that following transplantation, the pro-neural differentiation factors such as RA 
are lost or reduced, allowing the CS-A hydrogel to instead promote NPC stemness 
and non-differentiation.  
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Figure 9. Astrocytic and non-differentiation of NPCs 14 days after 
transplantation. A) Representative images of GFP, Sox2, and GFAP co-
labelled cells in the infarct core 2 weeks after transplantation. B) Analysis of 
percentage of astrocytic and non-differentiated cells. n=6-8/group. * 
indicates p<0.05; two-tailed T-test. 
Following our analysis of neuronal, glial, and non-differentiation after 
transplantation, we next sought to determine whether our cellular treatments may 
bypass the inhibitory glial scar to participate in neuronal replacement within the 
stroke core. We performed MAP2 and GFAP immunostaining to ascertain whether 
axons could pass through the glial scar. We found numerous cells expressing the 
axonal marker MAP2 within the stroke core region (Figure 10. However, the axons 
appeared to be strictly limited to within the stroke core region and ran parallel to 
the glial scar. We were unable to find any evidence that suggested Map2+ axons 
 85 
traversed the astrocytic barrier. These findings suggest that while CS-A may permit 
neuronal differentiation of NPCs in vitro and in vivo, the strategy of targeting 
transplantation to the infarct core region may not be conducive to replacing the 
axonal connections lost to stroke.  
 
Figure 10.  Formation of axons within the stroke core region. A) 
Representative images of contralateral axonal expression patterns and 
axonal expression within the stroke core region 2 weeks after 
transplantation. B) Insets from panel A) illustrate axons travel parallel to the 
astrocytic barrier and do not traverse the astrocytic barrier.  
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5.2  Aim 2: Determine the effects of treatment with CS-A encapsulated NPC 
on regeneration in the ischemic brain. 
5.2.1 Effect of CS-A encapsulation of NPCs on astrogliosis 
Astrogliosis entails reactive astrocytosis and the formation of the glial scar 
surrounding the infarcted tissue. These processes involve both the migration of 
activated astrocytes to the infarct region, and also the production of new astrocytes 
locally. The extent of the glial scar formation is thought to reflect the extent of 
damage and inflammation within the stroke core. Similarly, reactive astrocytosis, 
which includes the upregulation of GFAP in astrocytes and a transition from an 
ameboid to a stellate morphology, may signify the inflammatory state of the brain 
parenchyma [108, 114, 322, 323, 349]. Whether the hydrogel encapsulated neural 
progenitors may affect the astrocyte response to the infarcted cortex was 
unknown. We measured glial scar width and intensity of GFAP staining 2 weeks 
after transplantation using ImageJ. The average glial scar width was not 
significantly different between treatment groups, however, the intensity of GFAP 
staining in the peri-infarct region was significantly reduced in the CS-A + NPC 
treatment group compared to the cellular therapy and stroke controls (Figure 11). 
This suggests that treatment with CS-A encapsulated neural progenitor cells may 
abrogate the astrocytic response following transplantation.  
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Figure 11. CS-A encapsulation reduces peri-infarct GFAP staining intensity. 
Representative images of GFAP staining of the infarct and peri-infarct region 
and analysis of glial scar width and GFAP staining intensity were measured 
using ImageJ at 2 weeks after transplantation. n=8-12. ** indicates p<0.005; 
1-way ANOVA with Bonferonni correction.   
5.2.2 Treatment with CS-A encapsulated NPCs promotes a pro-regenerative 
macrophage response 
Microglial infiltration and production and release of immune factors is the major 
inflammatory response associated with cerebral infarction [100, 102, 107]. Certain 
microglial phenotypes, in particular the alternatively activated ‘M2’ phenotype, is 
associated with neural regeneration, angiogenesis and arteriogenesis, and 
functional recovery [102, 103, 331]. Cellular therapy and also implantation of 
hydrogels such as hyaluronan can affect microglial polarization and even promote 
local immunosuppression [34, 307, 350, 351]. Previous studies in our lab have 
shown that transplantation of NPCs is broadly immunosuppressive, and reduces 
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multiple harmful inflammatory mediators and the number of infiltrating microglia 
[6]. Similarly, transplantation of BMSCs also drastically reduces inflammation 
[307].  The microglial/macrophage response to CS-A and CS-A encapsulated 
NPCs is uncharacterized.  
To test the effects of treatment with CS-A + NPCs, we used 
immunohistochemical and protein expression analysis to probe microglial-related 
inflammatory markers. Following 2 weeks after transplantation, the number of M2 
type macrophages/microglia is significantly increased by CS-A + NPC treatment 
as determined by counting of PPARγ (an M2 marker) and IBA1 (a microglial 
marker) co-staining in the stroke area compared to the stroke and cellular 
treatment control. This suggests that transplantation of CS-A encapsulated neural 
progenitor cells markedly increases the amount of pro-regenerative microglia in 
the stroke area.  
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Figure 12. CS-A + NPC treatment promotes alternatively activated microglia 
polarization 2 weeks after intracranial transplantation. A) Representative 
images of PPARγ (an M2 marker) and IBA1 (a microglial marker) co-staining 
in the stroke area 2 weeks after transplantation. B) Analysis of number of 
PPARγ/IBA1 co-staining. n=8-12. **indicates p<0.005; 1-way ANOVA with 
Bonferonni correction.  
Next, we used Western blotting to probe the amount of IL-10 accumulated 
in the stroke area. IL-10 is produced primarily by microglia/macrophages and is 
thought to be a primary mediator in inducing an alternatively activated microglial 
phenotype. [100, 102-104, 107, 307, 331]. We have also shown that iPSC-derived 
NPCs and BMSCs can produce and release IL-10 [6, 296]. Furthermore, CS-A has 
a high affinity for IL-10, and in in vitro experiments, was shown to enrich IL-10 
following neural stem cell encapsulation [53, 324]. We also measured the amount 
of IBA1 expression in the infarct core region (Figure 13). We found that the 
interleukin 10 (IL-10) levels were significantly increased in the CS-A + NPC 
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treatment group compared to all controls (Figure 13). The macrophage marker was 
significantly reduced in the NPC treatment group compared to the stroke control 
and the combined CS-A + NPC treatment group, which is consistent with previous 
findings that transplanted NPCs can suppress the inflammatory response.  
 
Figure 13. CS-A+NPC treatment significantly enhances IL-10 protein levels 
in the stroke core region 1 week after transplantation. n=4-8. *, **, and **** 
indicate p<0.05, p<0.005, and p<0.0001, respectively; 1-way ANOVA with 
Bonferonni correction. 
To further probe the expression of immune mediators within the stroke 
region after treatment with CS-A encapsulated NPCs, we measured the 
expression of a variety of released factors, including monocyte chemoattractant 
protein 1 (MCP-1), macrophage inflammatory protein 1a and 1b (MIP-1a, MIP-1b), 
tumor necrosis factor (TNF), and interluekins 4 and 6 (IL-4, IL-6). Expression of 
these factors were interrogated at both the infarct core and the peri-infarct regions. 
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We found that at the stroke core region, MCP-1 was significantly increased by CS-
A encapsulation of NPCs compared to all other treatments (Figure 14). MCP-1 is 
a released factor involved in the recruitment of microglia/macrophages. Following 
ischemic injury and in various treatment paradigms, MCP-1 has been shown to 
recruit specific subsets of macrophages that participate in regeneration, including 
angiogenesis, arteriogenesis, and even neurogenesis [176, 196, 206, 214, 328]. 
MIP-1a and MIP-1b also participate in the recruitment of microglia/macrophages, 
however, they are more associated with the classically activated M1 macrophage 
phenotype, which is involved in neurotoxicity and infarct progression during the 
early phases of stroke pathophysiology [100, 106]. MIP-1a and MIP1b levels were 
significantly reduced by NPC transplantation compared to the stroke control and 
also the CS-A encapsulated NPC group Figure 14. There was no significant 
increase in MIP-1a/b expression in the CS-A encapsulated NPC group compared 
to the stroke and hydrogel controls. These findings are consistent with our work 
and others showing that transplanted NPCs are broadly immunosuppressive and 
can reduce microglial infiltration and activity. Similarly, IL-4 levels were also 
significantly reduced by NPC treatment compared to the stroke control and the CS-
A + NPC groups (Figure 14). In the context of microglial inflammation, IL-4 is a 
released protein which inhibits the M1 polarization of microglia/macrophages, 
thereby promoting M2 polarization [102-104, 106, 200]. IL-4 is also neuroprotective 
and can promote neurogenesis after brain ischemia [102-104, 106, 200].  
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Figure 14. Expression of released immune factors within the stroke core 
region 1 week after transplantation. n=3-4. * indicates p<0.05; 2-way ANOVA 
with Holm-Sidak correction. 
Together, these released immune factor expression findings suggest that 
CS-A encapsulation of NPCs may promote recruitment of regenerative 
macrophages via increase of MCP-1. Furthermore, these findings verify that 
treatment with NPCs can reduce both harmful and beneficial microglial 
inflammation, and that encapsulation with CS-A may allow expression recovery of 
some of these proteins. The extent to which CS-A can facilitate beneficial versus 
harmful microglial inflammation is not easily discernable. However, it should be 
noted that in all cases except for MCP-1, the expression levels in the CS-A + NPC 
treatment group were not statistically significantly different than the stroke controls. 
These samples were isolated from stroke tissue weeks after infarction, which is 
long after the initial wave of neurotoxic inflammation during the acute phases of 
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ischemic stroke [100, 106, 331]. This suggests encapsulation with CS-A does not 
worsen the inflammatory response compared to the natural history of inflammation 
in stroke pathology.  
 
Figure 15. Expression of released immune factors within the peri-infarct 
region 1 week after transplantation. * indicates p<0.05; 2-way ANOVA with 
Holm-Sidak correction. 
 The expression of the same proteins was also measured in the peri-infarct 
region (Figure 15). We found that MCP-1 was also significantly upregulated in the 
peri-infarct region of mice treated with CS-A encapsulated NPCs, suggesting that 
the recruitment of pro-regenerative microglial, in particular the recruitment of 
arteriogenic macrophages, extends outside of the stroke core region and into the 
peri-infarct zone. There was no significant difference in expression of other factors 
in the peri-infarct region. We also compared the total expression patterns of the 
immune factors in the stroke core region versus the peri-infarct region in mice 
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treated with CS-A encapsulated NPCs (Figure 16). The group expression was 
significantly reduced in the peri-infarct region compared to the stroke core region.  
 
Figure 16. Comparison of immune factors in the stroke core versus peri-
infarct region in CS-A+NPC treated mice 1 week after transplantation. **** 
indicates p<0.0001. Two-way ANOVA with Holm-Sidak correction.  
We compared the overall relative expression of these factors by treatment 
group to ascertain whether or not the group expression profiles as a whole were 
significantly different from each other. We found that the CS-A + NPC group 
expression of immune factors was significantly increased compared to all controls 
(Figure 17). Furthermore, the NPC treatment group was significantly reduced 
compared to the stroke control. These findings are in line with previous findings 
that intracranially transplanted NPCs are broadly immunosuppressive. 
Interestingly, the combination of the NPCs with the CS-A hydrogel seems to 










core region. This may due to the increased recruitment of M2 type macrophages 
observed in previous experiments (Figure 12).   
 
Figure 17. Analysis of group relative expression of immune factors 2 weeks 
following intracranial transplantation. ***, and **** indicate p<0.0005 and 
p<0.0001, respectively. Two-way ANOVA with Holm-Sidak correction.  
 


























Next, we tested whether the CS-A hydrogel may have direct effects on 
microglia/macrophages. Microglia were isolated from the stroke core region at 3 
days after infarction and either directly encapsulated in CS-A or plated on tissue 
culture polystyrene (Figure 18). We initially chose to isolate macrophages at 3 days 
after stroke since the infiltration peaks at this timepoint, allowing for collection of 
sufficient numbers for in vitro applications. Furthermore, microglia are more active 
at this timepoint [100, 103, 104, 331].  
 
Figure 19. CS-A encapsulation of stroke macrophages promotes a 
regenerative macrophage phenotype in vitro. A) Western blotting of 
VEGFR2, TIE2, PPAR, bFGF, and IL-10. B) Analysis of protein expression. 
n=3-5 in vitro replicates of macrophages pooled from 8 mice. * indicates 
p<0.05; two-tailed T-test. 
After 3 days in vitro, we found that microglia grown in the CS-A hydrogel 
expressed higher levels of VEGFR2, TIE2, PPARγ, bFGF, and IL-10 as 
determined by Western blotting (Figure 19). On macrophages, VEGFR2 and TIE2 
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expression, which correspond to the angiogenic/arteriogenic receptors for VEGF 
and Ang respectively, are involved in promoting vascular regeneration. Similarly, 
macrophages can produce bFGF, which can promote both angiogenesis and 
arteriogenesis. The enhanced expression of VEGFR2, TIE2, and bFGF suggests 
that CS-A encapsulation may promote macrophages to assist in vascular 
regeneration. The M2 associated proteins PPARγ and IL-10 were also significantly 
increased, suggesting that CS-A may play a role in promoting M2 macrophage 
polarization.  
CS-A can regulate IL-10 binding, partitioning, and presentation [47, 53, 
324]. Thus, we tested whether IL-10 may play a role in promoting the macrophage 
phenotype seen in vitro by neutralizing released IL-10 by addition of an anti-IL-10 
neutralizing antibody to the cell culture media (Figure 20). Microglia for this 
experiment were isolated at 7 days after infarction. This timepoint was chosen 
since it was believed the macrophages at this timepoint may better reflect those 
present at the stroke core during transplantation. We found that following 3 days 
in culture, all CS-A encapsulated groups showed increased TIE2 expression 
compared to the non-encapsulated macrophages. TIE2 expression was 
independent to addition of IL-10 neutralization antibody in either group. The levels 
of bFGF and PPARγ were reduced by addition of anti-IL-10 in the non-
encapsulated microglia, but not in the encapsulated group. This may suggest that 
IL-10 does not play a major role in determining CS-A mediated macrophage 
polarization. However, the levels of bFGF and PPARγ were similar in the CS-A 
encapsulated group versus the non-encapsulated group, which is contrary to the 
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results found in the previous experiment Figure 19. This suggests that the timing 
of macrophage isolation from the stroke core tissue is important in determining 
their response to the CS-A hydrogel. We hypothesize that the macrophages 
isolated at 7 days following infarction may be more senescent and less responsive 
to alterations in their physical environment or to IL-10 signaling, and thus, are not 
idea for the study of the role of IL-10 in CS-A mediated macrophage polarization 
[100].  
For these reasons, the experiment was repeated with stroke core 
macrophages isolated from tissue 3 days (rather than 7 days) after stroke. The 
experimental conditions were nearly identical except for the timepoint at which the 
macrophages/microglia were dissected from the stroke core region. We found that 
the protein levels of TIE2 and bFGF were significantly increased by CS-A 
encapsulation, which is consistent with previous in vitro and in vivo findings. 
Furthermore, IL-10 neutralization resulted in reduction in TIE2 and bFGF in both 
the CS-A encapsulated and non-encapsulated treatment groups. This suggests 
that IL-10 plays a role in promoting macrophage arteriogenic phenotype 
irrespective of encapsulation.  
An important limitation of these in vitro studies is that the macrophages 
isolated from the stroke core and subsequently cultured in vitro may not reflect 
their phenotype in vivo. Furthermore, for this experiment, the 
macrophage/microglial interaction with the transplanted NPCs was not evaluated, 
which appears to be a major influence on immune factor expression in vivo (Figure 
17). Another important limitation is that the dissection and culturing of the stroke 
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core tissue following dissociation does not yield a pure population of 
microglia/macrophages. Other cell types contaminants from the stroke core such 
as surviving endothelium or neurons may be present, however, they are very few 
and likely do not provide a significant contribution to the protein isolated for these 
experiments [74]. Also, the use of a neutralizing antibody may not completely 
reduce the levels of IL-10; alternate strategies such as genetic knockdown or 
knockout may provide more definitive reductions in bioavailability of IL-10. Finally, 
as discussed above, the timing of isolation of the stroke core tissue appears to be 
of critical importance. Macrophages isolated at early time points (3 days) may be 
primed to respond to the ischemic injury and may exhibit more plasticity in their 
response to CS-A encapsulation and IL-10 neutralization [100]. This may explain 
the discrepancy in response to IL-10 neutralization and overall expression of pro-
arteriogenic markers in the macrophages isolated at early versus later timepoints.  
 
Figure 20. Experimental design for testing the role of IL-10 on CS-A mediated 
macrophage polarization in vitro.  Stroke core macrophages were dissected 
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at either 7 (Figure 21) or 3 days (Figure 22)  after surgical induction of cortical 
ischemia (Primary stroke core macrophage isolation and culture).  
 
 
Figure 21. IL-10 neutralization may abolish the regenerative capability of 
stroke core microglia/macrophages collected 7 days after stroke. A) Western 
blotting of TIE2, PPAR, and bFGF. B) Analysis of protein expression. n=3-6 
in vitro replicates of pooled macrophages from 10 mice. * indicates p<0.05; 
1-way ANOVA with Bonferroni correction.  
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Figure 22. IL-10 neutralization reduces pro-arteriogenic markers in 
microglia/macrophages collected 3 days after stroke. A) Western blotting of 
TIE2 and bFGF. B) Analysis of protein expression. n=3 in vitro replicates of 
pooled macrophages from 3 mice per treatment group (3 separate mice per 
treatment; 12 mice total). * indicates p<0.05; 1-way ANOVA with Bonferroni 
correction. 
5.2.3 Neurogenesis and neuroblast recruitment are unaffected by treatment 
The endogenous replacement of neurons lost to stroke is a possible mechanism 
of recovery. To test whether treatment can promote endogenous neurogenesis, 
we injected mice daily (after treatment) with BrdU which labels newly formed cells. 
The number of NeuN (neuronal marker) and BrdU colabelled cells were counted. 
We found that the levels of newly formed neurons across all treatment groups and 
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controls was extremely low (~0.2 cells per section). There was no difference in 
neurogenesis between treatment groups (Figure 23). Prior to the endogenous 
formation of newborn neurons, doublecortin (DCX) + neuroblasts migrate from the 
subventricular zone to the peri-infarct region over the course of days to weeks [22, 
111, 180, 305]. We counted the number of migrating neuroblasts in the peri-infarct 
region and also measured the intensity of DCX expression in the subventricular 
zone. We found that there was no significance between treatment groups in DCX 
levels at the peri-infarct or SVZ (Figure 23). Together, these findings indicate that 
CS-A encapsulation of NPCs does not promote neuronal regeneration. Cellular 
therapy in other treatment paradigms, such as transplantation of these same iPSC 
derived NPCs directed to the peri-infarct, and intranasal delivery of BMSCs, has 
been shown to promote neurogenesis following treatment after stroke [6, 7, 23, 35, 
186]. Since we found no improvements in neurogenesis, this may suggest that 
targeting the infarct core for transplantation may not be a viable strategy for 
inducing neurogenesis after stroke.   
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Figure 23. CS-A + NPC treatment directed to the stroke core does not 
improve neurogenesis after stroke. A) Representative images of NeuN/BrdU 
and DCX staining at the peri-infarct region (top panel) and SVZ 2 weeks after 
intracranial transplantation. B) Analysis of neurogenesis, SVZ DCX staining 
intensity, and number of peri-infarct DCX+ neuroblasts. n=8-12. * indicates 
p<0.05; 1-way ANOVA with Bonferroni correction.  
Next, we tested whether treatment with CS-A+NPCs may affect protein 
expression of neurogenic factors. Using Western blotting, we measured the levels 
of BDNF and NGF, both of which have been shown to be enriched within CS-A 
hydrogel in vitro [53, 324]. We found that levels of brain derived neurotrophic factor 
(BDNF) were significantly increased in the CS-A+NPC treatment group compared 
to all other controls (Figure 24). However, the levels of nerve growth factor (NGF) 
were not statistically different between groups. BDNF is associated with both 
neurogenesis and neural plasticity [35, 352]. The neurogenesis results above 
(Figure 23) indicated that neurogenesis was unaffected in any treatment group. 
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Therefore, it is unlikely that the increased BDNF levels in the stroke core region 
played a role in endogenous neurogenesis. Furthermore, given that the axons 
produced in the stroke core were unable to penetrate the astrocytic barrier, it is 
unlikely that the enhanced BDNF levels promoted synaptic plasticity in the stroke 
core. Others have shown that BDNF is also neuroprotective during brain ischemia 
[352]. It is possible that increased levels of BDNF within the CS-A hydrogel 
promoted enhanced retention and resistance to cell death following transplantation 
into the infarct core. However, synaptic plasticity in the stroke core or the peri-
infarct region, and the effect of BDNF on transplant cell retention were not tested 
and are potential areas for future study. 
 
Figure 24. CS-A+NPC treatment increases BDNF expression in the stroke 
core region 1 week after transplantation. BDNF levels were increased in the 
CS-A+NPC group compared to all controls. NGF levels were not statistically 
different between groups. n=4-8. * indicates p<0.05; 1-way ANOVA with 
Bonferonni correction.  
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5.2.4 Vascularity and angiogenesis are increased by CS-A+NPC treatment 
Vascular regeneration is at the center of recovery processes following cerebral 
infarction. To assess the potential for angiogenic benefits of CS-A encapsulation 
of NPCs, we treated mice daily with BrdU to monitor newly formed cells. The 
number of Glut1+ microvessels co-labelled with BrdU were counted, and the total 
number of microvessels within the stroke core region were also counted to 
measure newly formed endothelium and vascular density. We found that CS-A 
encapsulation of NPCs significantly improves their potential to induce 
angiogenesis, resulting in a greater number of newly formed endothelium, and a 
higher density of blood vessels within the stroke core region (Figure 25). We also 
noted formation of numerous muscular arteries (SMA+, Glut1+ vessels) within the 
hydrogels in mice treated with CS-A + NPCs (Figure 26).  
We probed signaling pathways that are involved in induction of 
angiogenesis using Western blotting. We found that bFGF and VEGF were 
significantly elevated in the CS-A+NPC group compared to all controls. These two 
molecules are well-known for their important roles as mediators of angiogenesis 
and vascular remodeling in health and disease [252, 353-355]. Furthermore, we 
also found that p-AKT was also upregulated in CS-A+NPC compared to the stroke 
and cellular controls. At the cellular level, enhanced AKT signaling reflects growth 
and proliferation, suggesting that regenerative processes such as angiogenesis 
are enhanced by treatment with CS-A+NPCs. However, we cannot rule out the 
expression of p-AKT in cell types other than endothelium, including microglia, 
astrocytes, or the transplanted cells. 
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Figure 25. CS-A encapsulation of NPCs improves angiogenesis and stroke 
core vascularity. A) Glut1 and BrdU costaining. B) Analysis of angiogenesis 
(#Glut1/BrdU co-labelled endothelium). C) Analysis of vascularity. n=8-12. *, 
**, and *** indicate p<0.05, p<0.005, and p<0.001, respectively; 1-way ANOVA 
with Bonferonni correction. 
The relative cellular contributions of bFGF within the stroke core are 
unclear. Numerous cell types can produce and release bFGF, including 
macrophages/microglia, endothelial cells, vascular mural cells, astrocytes, 
neurons, and transplanted NPCs. However, given the robust generation of bFGF 
by stroke core macrophages in vitro (Figure 19), we hypothesize that 
microglia/macrophages are a likely candidate for the main source of bFGF. This 
hypothesis is also consistent with findings in the literature regarding the role of 
microglia/macrophages in vascular regeneration [102, 205, 328, 331]. 
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Figure 26. Representative image of a muscular artery (SMA/Glut/BrdU) 
formation within the hydrogel of mice treated with CS-A + NPC.  
 
Figure 27. Increased expression of angiogenic proteins after treatment with 
CS-A+NPC. A) Western blotting of bFGF, p-STAT3, p-AKT, and VEGF. B) 
Analysis of angiogenic protein expression. *, **, and **** indicates p<0.05, 
p<0.005, and p<0.0001, respectively; 1-way ANOVA with Bonferonni 
correction. 
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 Angiogenesis entails the migration and proliferation of endothelial cells. We 
next sought to test whether the CS-A hydrogel may have an effect on either of 
these processes. To test for endothelial migration and haptotaxis, we used a 
microfluidic device developed by our collaborators [338] which allows for the 
comparison of migration into either a CS-A or hyaluronan hydrogel (Figure 28). 
Without any type of haptotapic signal (i.e. regular media), immortalized brain 
endothelial cells (B.end3) migrated equally into the CS-A and hyaluronan gels. 
However, when a haptotactic gradient was applied using NPC-conditioned media, 
the endothelial cells preferred to migrate towards the CS-A hydrogel (Figure 28). 
We also tested whether CS-A may affect proliferation using Western blotting for 
the cell cycle protein Cyclin D1 (Figure 29). We found there was no difference in 
Cyclin D1 expression in the CS-A encapsulated versus the non-encapsulated after 
3 days in vitro.  
 
Figure 28. CS-A promotes NPC-mediated endothelial haptotaxis (Hydrogel 
haptotaxis assay). n=3. ** indicates p<0.005; 1-way ANOVA with Bonferonni 
correction.   
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Figure 29. CS-A may not affect endothelial replication in vitro. Western 
blotting analysis indicates CyclinD1, a cell cycle protein and marker for 
replication, was not different between groups. n=3; two-tailed T-test.   
Together, these in vitro results suggest that CS-A can promote endothelial 
migration via released signals from NPCs which were available in the conditioned 
media. However, CS-A did not appear to affect levels of markers of endothelial 
replication, suggesting that the major mechanism by whicih CS-A  encapsulation 
may promote angiogenesis is via recruitment of new endothelial cells.  
5.3  Aim 3 Determine the effects of treatment with CS-A encapsulated NPCs 
on local blood flow restoration and functional recovery after ischemic 
stroke. 
5.3.1 CS-A encapsulation of NPCs augments blood flow to the infarcted cortex 
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Blood flow to the cerebral cortex is a critical aspect of recovery and regeneration 
after ischemic stroke. We tested cortical circulation after stroke and treatment 
using laser Doppler flowmetry to measure local cerebral blood flow (LCBF) in the 
stroke area (Figure 30). The LCBF was monitored before and weekly after stroke.  
 
Figure 30. Diagram of cortical areas measured using laser Doppler flowmetry 
and representative pre-stroke and post-stroke flow heatmaps (Mouse stroke 
model, laser Doppler flowmetry, and transplantations).  
We found that blood flow to the infarcted cortex was increased following treatment 
with CS-A+NPCs at both 1 and 2 weeks after treatment compared to all controls 
(Figure 31). At 1 week after stroke, we noted that blood flow recovery was also 
improved by treatment with NPCs, but to a lesser extent than by CS-A 
encapsulated NPCs. However, the improvement in blood flow from non-




Figure 31. CS-A encapsulation improves cortical blood flow after stroke. The 
top panel illustrates LCBF heatmaps at 2 weeks after transplantations 
(Mouse stroke model, laser Doppler flowmetry, and transplantations). n=8-
12. * and **** indicates p<0.05 and p<0.0001, respectively; 2-way ANOVA with 
Bonferroni correction. 
5.3.2 Pial collateral artery diameter and recruitment are increased with CS-A 
encapsulation of NPCs 
We hypothesized that cellular therapy may improve the structural 
remodeling of large vessels after stroke. To examine pial artery remodeling and 
collateralization after treatment, we utilized mice with alpha smooth muscle actin 
tagged with GFP (SMA-GFP). Mice brains were isolated following conclusion of 
the experiments and imaged using a fluorescent microscope. The number and 
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widths of pial collateral arteries was collected and analyzed. A recruited collateral 
was defined as a collateral vessel with at least 25% greater diameter than the 
average sham collateral vessel diameter, which corresponds to >50% increase in 
flow rate through the collateral channel. We found that average pial collateral 
diameter and collateral recruitment were significantly improved by CS-A 
encapsulation (Figure 32). Collateral number was not significantly different 
between groups, affirming that collaterogenesis, or the de novo formation of 
anastomoses, is not a prominent phenomenon in our ischemic stroke model and 
is unaffected by treatment. We verified that the arteriogenesis was due to outward 
remodeling of large pial arteries using immunohistochemistry (Figure 33). Large 
arteries undergoing outward remodeling (SMA+/BrdU+ vessels) in the pial layer of 
the meninges were found in both the peri-infarct region and in the stroke core area.  
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Figure 32. Treatment with CS-A+NPCs improves pial artery collateralization 
after stroke. A) Representative images of pial collaterals; red box indicates 
MCA-ACA anastomoses in similar locations between animals. B) Analysis of 
collateral vessel number. C) Analysis of average collateral vessel width. D) 
Analysis of pial collateral recruitment. n=8-12. * and **indicates p<0.05 and 
p<0.005, respectively; 1-way ANOVA with Bonferroni correction; all groups 




Figure 33. Confirmation of outward remodeling in pial vessels following 
treatment with CS-A + NPC. A) Representative image of pial artery in the peri-
infarct region with numerous SMA/BrdU colabelled cells. B) Representative 
image of pial artery in the stroke core region with multiple SMA/BrdU 
colabelled cells.   
5.3.3 CS-A encapsulation of NPCs fails to provide additional functional benefits 
in sensorimotor tests after ischemic stroke 
Recovering functional deficits lost to stroke is the primary goal of therapy. Our 
ischemic stroke model targets the sensorimotor cortex responsible for mouse 
whisker and forelimb sensation and motor function [177, 186, 215]. We evaluated 
whisker sensation using the corner test. Mice tend to turn right following stroke due 
to a lack of sensation of the left whiskers, resulting in an elevated right/left turn. 
Two weeks after stroke, the CS-A+NPC group showed a reduced rightwards 
deviation compared to the stroke control, but not the cellular or material controls. 
Forepaw sensorimotor function was evaluated using the adhesive removal test. 
Mice treated with CS-A + NPCs showed a significantly improved time to removal 
1 week after transplantation compared to the stroke control, but not to the cellular 
or material control groups.  
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Figure 34. Corner and adhesive removal test performance after treatment. 
n=8-12. *, **, ***, and **** indicates p<0.05, p<0.005, p<0.0005, and p<0.0001, 
respectively; 2-way ANOVA with Bonferroni correction.  
General motor coordination and balance was assessed using the rotarod 
test, where the time to fall off a rotating wheel is compared. We found that at 1 and 
2 weeks after transplantation, mice treated with either NPCs or CS-A encapsulated 
NPCs showed a greater ability to stay on the rotating rod compared to stroke 
controls, but not to CS-A acellular hydrogel controls (Figure 35). This suggests that 
CS-A encapsulation does not improve NPC-mediated functional improves in motor 
coordination and balance after stroke.  
Forepaw motor function was tested using the volitional isometric pull test. 
These tests required extensive training for the mice, therefore, we opted to 
eliminate the CS-A acellular control which showed no effect in the previous 
behavior studies. Two weeks after transplantation, mice treated with CS-A + NPC 
showed improved pull strength compared to the stroke control, but not the cellular 
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control. The pull test successful hit rate was significantly increased in the CS-A + 
NPC treatment compared to the cellular treatment, but not the stroke control.  
 
Figure 35. Rotarod test performance after transplantation. n=8-12. *, **, ***, 
and **** indicates p<0.05, p<0.005, p<0.0005, and p<0.0001, respectively; 2-
way ANOVA with Bonferroni correction. 
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Figure 36. Isovolumetric pull test performance after treatment. n=3-4 *, **, ***, 
and **** indicates p<0.05, p<0.005, p<0.0005, and p<0.0001, respectively; 2-
way ANOVA with Holm-Sidak correction. 
Post-stroke neuropsychiatric deficits have also been reported in humans 
and in rodent stroke models. We tested the possibility that treatment may affect 
these outcomes (Figure 37). The open field test assesses anxiety-like behavior by 
monitoring the proportion of time the mice spend in the center of the arena; it can 
also be used to gather sensorimotor data such as distance travelled and average 
velocity during the test. We found that all treatment groups showed an increased 
time spent in the center of the arena, suggesting they have reduced anxiety 
compared to the stroke control; there were no differences between the 
transplantation groups. Furthermore, there were no differences in average travel 
distance or velocity between treatment groups. The tail suspension test assesses 
apathy-like behavior. We found that mice treated with the CS-A + NPC treatment 
have reduced immobility time compared to the stroke and cellular controls, 
suggesting they have reduced apathy-like behavior (Figure 37). However, there 
was no difference between the CS-A acellular hydrogel and the combined CS-A + 
NPC group. These results suggest that CS-A encapsulation may improve post-
stroke apathy-like behavior, however, encapsulation does not affect anxiety-like 
behavior.  
Next, we tested the overall relative performance in the sensorimotor 
behavior tests by treatment group at 2 weeks following transplantation to ascertain 
whether or not the group sensorimotor performance profiles as a whole were 
significantly different from each other. We found that there was no statistically 
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difference between overall sensorimotor test performance between groups (Figure 
38). This suggests that CS-A encapsulation of NPCs, under the treatment 
paradigms and strategies implemented for this work, are not effective at facilitating 
sensorimotor recovery after ischemic stroke.   
 
Figure 37. Recovery of post-stroke neuropsychiatric deficits following 
treatment. n=8-12. * indicates p<0.05; 2-way ANOVA with Bonferroni 
correction.  
 
Figure 38. Analysis of group relative sensorimotor test performance 2 weeks 
after ischemic stroke. Two-way ANOVA with Bonferroni correction. CS-
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A+NPC vs NPC p=0.6722; CS-A+NPC vs No treatment p=0.0604. NPC vs no 
treatment p=0.2334.   
5.3.4  Neutralization of bFGF abolishes CS-A + NPC-mediated improvements in 
vascular regeneration and blood flow recovery  
A major benefit of CS-A encapsulation appears to be highly improved vascular 
regeneration and blood flow recovery. CS-A has a high affinity for bFGF which is 
known to play a key role in these processes, and in our previous experiments, was 
found to be increased in the stroke core region (Figure 27). Thus, we sought to 
determine whether bFGF plays a critical role in CS-A+NPC mediated vascular 
regeneration and blood flow recovery. To test this possibility, we administered a 
neutralizing antibody towards bFGF (anti-bFGF) concurrently with CS-A+NPC 
transplantation (CS-A+NPC+anti-bFGF). This group was compared head to head 
with the CS-A encapsulated NPC group (Figure 39). We measured and compared 
angiogenesis, pial artery dynamics, and local cerebral blood flow 2 weeks after 
treatment using the same methods described above (Figure 25, Figure 31, Figure 
32). Furthermore, we also measured whisker function using the corner test, since 
this was our most sensitive test at 3 weeks after cerebral infarction.  
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Figure 39. Experimental design for bFGF neutralization animal experiments.  
 
Figure 40. Neutralization of bFGF abolishes vascular regeneration and blood 
flow in CS-A+NPC treated mice following ischemic stroke. A) Representative 
images of Glut1/BrdU costaining for angiogenesis, pial collateralization, and 
local cerebral blood flow in the stroke region 2 weeks after stroke. B) 
Analysis of angiogenesis, pial collateral recruitment, cortical blood flow, and 
corner test. n=4-5. *, **, and *** indicates p<0.05, **p<0.005, ***p<0.0005 
respectively; two-tailed T-test. 
We found that addition of the bFGF neutralizing antibody into the hydrogel prior to 
transplantation resulted in significant reduction in the number of Glut1/BrdU 
colabelled cells in the stroke region (Figure 40). Furthermore, the extent of 
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collateralization was also reduced as measured by the percentage of recruitment 
of pial collateral arteries. Correspondingly, the amount of blood flow recovery 
measured by laser Doppler was reduced (Figure 40). Whisker functional recovery 
was reduced with addition of the bFGF neutralizing antibody as the CS-
A+NPC+anti-bFGF group showed a higher rightwards deviation in turning 
behavior. Taken together, and with consideration of the vascular repair results 
detailed in Aim 2, these results suggest that bFGF plays an important role in 
mediating the angiogenic and arteriogenic regeneration and repair induced by 




6.1  CS-A encapsulation of NPCs increases transplant retention, elicits a pro-
regenerative inflammatory response, and augments vascular 
regeneration and blood flow after ischemic stroke 
Growing evidence suggests that the transplantation of neural progenitor cells may 
be a viable approach to regenerate brain tissue lost to stroke or other brain injuries. 
Despite their well-documented therapeutic effects in the lab, clinical trials thus far 
have not been as successful as expected [13, 290, 356]. Work in animals has 
identified key deficiencies in transplant cell retention, engraftment, differentiation, 
and ability to generate sufficient regenerative activities for functional recovery as 
major impediments to clinical translation [13, 104, 262, 290]. The present study 
investigates the therapeutic effects of encapsulated NPCs in a hydrogel matrix 
composed of chondrointin-4-sulfate A (CS-A) following transplantation into the 
ischemic stroke core.  
A primary outcome for transplantation studies is the successful survival, 
retention, and engraftment of transplanted cells. Using immunohistochemical 
methods and cell tracking of DiR labelled transplanted cells, we found that CS-A 
encapsulation reduces transplant cell death (Figure 2) and enhances cellular 
retention (Figure 4) following transplantation into the ischemic brain. We also 
determined that the CS-A hydrogel is amenable to neuronal differentiation in vitro 
(Figure 6) and in vivo (Figure 8) following transplantation. CS-A encapsulated 
NPCs can form axons/neurites, synapses, and express mature neuronal markers 
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following the differentiation protocol (Figure 6). Furthermore, following 
transplantation into the brain after stroke, CS-A appears to reduce glial 
differentiation of NPCs, which may be preferable to support neuronal replacement 
(Figure 9). However, in examination of axonal formation after transplantation, we 
found that transplantation to the stroke core region is not conducive to axonal 
formation through the inhibitory glial scar (Figure 10). This suggests that despite 
the increased retention and neural differentiation of transplanted NPCs 
encapsulated in CS-A, and also despite the reduction in peri-infarct reactive 
astrocytosis, neuronal replacement may not occur via transplant cell engraftment. 
It is likely that the inability of the CS-A + NPC treatment to reduce the thickness of 
the astrocytic scar (Figure 11) played a role in the failure of transplanted NPCs to 
develop axon and synapses which reached the viable parenchyma in the peri-
infarct region. The implications of this finding are further discussed in 6.2:  Pitfalls 
in CS-A + NPC therapy and transplantation directed to the infarct core region.  
The immune response plays a major role in the natural history of stroke 
pathophysiology and the response to transplanted materials [11, 27, 329, 330]. 
Microglia/macrophages are the major immune cells involved in stroke [103]. It is 
desirable for the hydrogel to either reduce harmful inflammation, remain immune-
inert, or promote a regenerative immune phenotype [41, 45]. The pro-regenerative 
M2-type macrophage population is associated with neurogenesis, angiogenesis, 
and stroke recovery, while the M1 response is inhibitory to recovery and 
associated with infarct progression [103, 331].  
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The microglial response to the transplanted CS-A encapsulated NPCs was 
interrogated using immunohistochemical, molecular biological, and cell culture 
techniques. We found that CS-A + NPC treatment enhanced microglial polarization 
towards the regenerative M2/alternatively activated phenotype (Figure 12) using 
immunohistochemical techniques. The immune response was further 
characterized by analyzing the protein expression of a variety of immune factors 
(Figure 13, Figure 14, Figure 15, Figure 16, Figure 17). We found that the 
immunomodulatory interleukin 10 (IL-10) was enhanced in the stroke core 
following encapsulated cellular therapy (Figure 13). The chemoattractant protein 
MCP-1, which is important for recruiting vascular associated macrophages to 
promote angiogenesis and arteriogenesis, was also significantly increased by CS-
A + NPC treatment compared to all other treatments (Figure 14). The group 
expression of immune factors was found to be different between treatment groups, 
suggesting that the combination of CS-A and the encapsulated NPCs, elicit 
different immune responses following treatment (Figure 17).  
Given the robust enrichment of IL-10 in the stroke core following treatment 
with CS-A + NPCs (Figure 13), and knowing that the CS-A sulfation moiety can 
facilitate IL-10 signaling[47, 53], we hypothesized the CS-A gel may act via IL-10 
to affect microglia/macrophage phenotype. We first tested the specific response of 
macrophages to the CS-A hydrogel in a controlled in vitro environment (Figure 18). 
We found that in vitro culture of primary stroke core macrophages/microglia in the 
CS-A hydrogel increased expression of proteins bFGF and IL-10, and markers 
such as VEGFR2, TIE2, and PPARγ, which are associated with a regenerative and 
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reparative macrophage phenotype (Figure 19). Using neutralization studies 
(Figure 20, Figure 21, Figure 22) in vitro, we also found that the immunomodulatory 
factor interleukin 10 may play a role in promoting a pro-arteriogenic 
macrophage/microglial phenotype, particularly in macrophages isolated 3 days 
after cerebral infarction (Figure 22).   
 The innate capability of the adult brain to create new neurons is inadequate 
to facilitate meaningful recovery after stroke. Formation of new neurovascular units 
is paramount to reestablishment of neuronal circuitry lost to infarction [332]. 
Intracranially transplanted iPSC-NPCs provide trophic support to the surrounding 
tissue via the production and release of regenerative factors [6, 7, 9]. 
Neovascularization in the hypoxic stroke region is necessary for the survival and 
success of both endogenously formed newborn neurons and transplanted iPSC-
NPCs and is also prognostic of recovery [176]. The interaction of released growth 
factors with surrounding ECM is a critical step of trophic support and growth factor 
mediated regenerative activities [28, 55, 333]. Following ischemic damage, the 
ECM is extensively degraded and is unable to fully support trophic enrichment 
offered by transplanted NPCs [37, 41, 57, 334]. CS-A is an ECM component of the 
endogenous neural stem cell niche and can bind, partition, and orchestrate 
signaling of BDNF, FGF, IL10, and other released factors important for healing [39, 
53]. These factors can promote endogenous neurogenesis and 
angiogenesis/arteriogenesis to facilitate recovery [5, 6, 9, 22, 36, 335]. We 
hypothesized that the combination of CS-A and NPCs may synergize to enhance 
the formation of new neurovascular units. 
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 The ability of CS-A encapsulated NPCs to facilitate neurogenesis was 
studied using immunohistochemistry. Contrary to our hypothesis, we found that 
the number of newly formed neurons was extremely low in all treatment groups 
and was not enhanced by CS-A encapsulation (Figure 23). Furthermore, the 
migration of neuroblasts from the SVZ to the peri-infarct region was similarly 
unaffected by CS-A encapsulation of NPCs or any treatment (Figure 23). The 
implications of these findings are further discussed in 6.2:  Pitfalls in CS-A + NPC 
therapy and transplantation directed to the infarct core region. 
 The effect of treatment on vascular regeneration was also tested. Our 
studies indicate that treatment with CS-A + NPCs significantly improves 
angiogenesis and vascular density within the stroke core region (Figure 25). 
Numerous arteries were detected within the hydrogel implant in mice treated with 
CS-A + NPCs (Figure 26). Protein markers of angiogenesis and vascular 
regeneration were also elevated, including bFGF and VEGF expression within the 
stroke core region (Figure 27). In vitro studies suggested that CS-A can enhance 
endothelial haptotaxis towards signals released by NPCs (Figure 28), but may not 
have effects on endothelial replication (Figure 29). Vascular remodeling of large 
pial arteries was monitored using genetically modified mice expressing alpha 
smooth muscle actin tagged with GFP (SMA-GFP). We found that treatment with 
CS-A encapsulated NPCs results in increased collateral artery diameter and 
augmented collateral recruitment (Figure 32). We verified that the collateralization 
was due to outward remodeling of the large pial arteries in the stroke core region 
and also in the peri-infarct region in mice treated with CS-A + NPCs (Figure 33). 
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In agreement with the vascular regeneration and repair effects following treatment 
with CS-A + NPCs, we found that blood flow to the infarcted cortex was also 
improved (Figure 31).  
 Given the central role of bFGF in angiogenesis and arteriogenesis, the 
ability of CS-A to bind, partition, and promote signaling of bFGF, and the finding 
that transplanted CS-A + NPCs can upregulate bFGF in the stroke core, we 
hypothesized this molecule may important for the vascular regeneration benefits 
provided by CS-A encapsulation. To test this possibility, we performed a head-to-
head comparison of CS-A encapsulated NPCs with or without the addition of a 
bFGF neutralizing antibody (Figure 39). In agreement with this hypothesis, we 
found that addition of the anti-bFGF antibody resulted in reduced angiogenesis, 
collateralization, and blood flow to the infarcted cortex (Figure 40). These findings 
suggest bFGF plays a central role in mediating the vascular regeneration and 
reparative effects of CS-A encapsulation.  
 Improving functional behavioral recovery is the primary goal of designing, 
testing, and implementing preclinical studies for disease. We tested behavioral 
recovery using methods specific to our sensorimotor cortex mini-stroke model. 
Results from the corner test, adhesive removal test, and isovolumetric volitional 
pull tests indicate that CS-A encapsulation is not superior to non-encapsulation, 
and rarely and inconsistently superior to the stroke controls (Figure 34). Analysis 
of the summary behavior findings illustrated no significant different between the 
stroke control, cellular control, material control, or combined treatment groups 
(Figure 38). We also assessed post-stroke neuropsychiatric deficits using tests for 
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anxiety and apathy (Figure 37). These tests were inconclusive.  The tail 
suspension test indicated that CS-A encapsulation may reduce apathy-like 
behaviour, however, the open field test showed no benefits for anxiety-like 
behaviour compared to the intermediate controls. The implications of these 
functional results are discussed in the section 6.2.2: CS-A encapsulation of NPCs 
failed to improve functional outcomes below.  
6.2  Pitfalls in CS-A + NPC therapy and transplantation directed to the infarct 
core region 
6.2.1 Cellular therapy targeted to the infarct core failed to provide neuronal 
replacement after ischemic stroke 
Neuronal replacement can occur via 1) differentiation and integration of 
transplanted cells into existing neuronal networks, or 2) mobilization of 
endogenous neural progenitors which following stroke, which migrate from the 
SVZ towards the peri-infarct region to become newborn neurons. While the CS-A 
hydrogel can improve retention and permit neuronal differentiation, we were 
unable to find evidence that axons formed within the stroke core of any treatment 
group could transverse the glial scar (Figure 10). This suggests that the 
transplanted cells may not be able to directly participate in the neuronal circuits to 
repair networks damaged by infarction. However, it is possible that the 
transplanted cells may be able to promote synaptic plasticity of neighboring 
endogenous neurons, although this was not tested. Furthermore, no treatments 
had any effect of endogenous neurogenesis, including formation of newborn peri-
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infarct neurons or migration or accumulation of migrating neuroblasts from the SVZ 
to the peri-infarct region (Figure 23). Together, these findings indicate that 
transplantation of CS-A+NPCs into the stroke core does not facilitate neuronal 
replacement by either endogenous or exogenous addition of neurons lost to 
cerebral infarction.   
6.2.2 CS-A encapsulation of NPCs failed to improve functional outcomes 
Recovering functional deficits lost to stroke is the primary goal of therapy and 
the overarching objective for encapsulating NPCs with CS-A. In the sensorimotor 
behaviour experiments described above, CS-A+NPC was occasionally better than 
the stroke controls but was consistently not superior to the material or cellular 
controls. Cumulatively, there was no difference in sensorimotor behaviour 
recovery between all experimental groups (Figure 38).  
There are multiple potential reasons for failure of the CS-A encapsulation of 
NPCs to yield statistically significant improvements in sensorimotor behavior 
following treatment. The first is the possibility of a type 2 error, or failure to reject 
the null hypothesis, which is that CS-A+NPC does not provide additional 
sensorimotor benefits. The studies described in this experiment may have been 
underpowered to make conclusive statements regarding potential behavior 
benefits. Originally, the experiments were powered for determining differences in 
local cerebral blood flow measurements. The power analysis estimated a minimum 
of 9 animals per group to find significant differences in blood flow, and 
approximately 12 were used per timepoint per group to allow for unpredicted 
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excess uncertainty. This may not have been sufficient to capture differences in 
behavior, which in this study, had large variation and a lower average effect size. 
If the behavior experiments were to be repeated, the sensorimotor behavior results 
produced in this study could be used as preliminary data for an additional power 
analysis focused on finding potential differences in behavioral outcomes. In the 
sensorimotor test with the greatest post-stroke deficit levels, the corner test (Figure 
34), the average effect size was 26.27% 2 weeks after transplantation. Assuming 
a power of 0.8 and determining significance at 0.05, an estimated sample size of 
41 animals per group is necessary to verify a difference between groups, if there 
is one to be detected. This estimation is over 3x the number used for many of the 
experiments in this work. Similarly, the average effect size of the sensorimotor 
behavior tests cumulatively is 23.30% at 2 weeks after treatment (Figure 38); 
approximately 53 animals/group are needed to determine if the treatments have 
differential effects on sensorimotor outcomes. These estimates suggest the 
behavior tests were underpowered and highlight the likelihood of a type 2 error. 
A second possibility for the failure of the sensorimotor tests to detect 
differences between treatment groups is that there are no differences to detect and 
we have made the correct inference in failing to reject the null hypothesis. This is 
also a likely possibility given the failure of the CS-A encapsulation of NPCs, or 
other treatment groups targeted to the stroke core, to facilitate meaningful neuronal 
replacement (Figure 10, Figure 23). Despite the other positive findings, functional 
behavior recovery may indeed be limited by the lack of neuronal replacement 
observed in our treatment paradigm.  
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Future efforts may also consider a different stroke model for the study of 
behavioral recovery. While the mini-stroke model is advantageous for the study of 
cellular and molecular mechanisms of therapy for stroke, the behavioral 
phenotypes are less severe than those in other models. For example, the middle 
cerebral artery occlusion (MCAo) model greatly extends the window for 
distinguishing behavioral deficits which may allow for better detection of 
differences in behavior outcomes between treatment groups [217]. However, 
stroke models with greater infarct sizes also carry the risk of hiding the possible 
benefits of therapy simply due to extent, severity, and possibly the irreversibility of 
brain damage. Regardless, the encapsulation of NPCs with CS-A should be tested 
in at least one other rodent stroke model and various other multiple other animal 
stroke models before the possibility of clinical translation, as dictated by the Stem 
Cell Therapy as an Emerging Paradigm for Stroke (STEPS) committee guidelines 
for preclinical studies [5].  
6.3  Opportunities for improvement of CS-A encapsulation of NPCs for the 
treatment of brain injuries  
We provide evidence of enhanced vascular regeneration/repair and augmented 
cortical blood flow in response to CS-A encapsulation of NPCs, nevertheless, this 
treatment fails to promote functional behavioral recovery. As it stands, the 
combination of the CS-A hydrogel scaffolding and neural progenitor cells directed 
towards the infarct core is not a viable treatment for ischemic stroke. However, 
additional approaches may be employed to overcome the limitations of the current 
strategy to fully utilize the beneficial effects of CS-A encapsulated NPCs.  
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 The lack of neuronal replacement is a major impediment for CS-A+NPCs 
transplanted into the stroke core region. Strategies to augment neuronal 
replacement may overcome this limitation to promote behavioral recovery. Since 
the adult brain has limited and saturatable endogenous capabilities to form new 
neurons after stroke [22, 180, 193, 305], neuronal replacement strategies may 
focus on addition of neurons exogenously and facilitation of neural integration of 
transplanted cells. The CS-A hydrogel is a versatile, multifunctional 
glycosaminoglycan with the capability of binding, enriching, and presenting a 
number of regenerative molecules, including brain derived neurotrophic factor 
(BDNF). BDNF plays a major role in axon formation during brain development, in 
formation of axons in neurons generated endogenously from the SVZ and SGZ, 
and in axonal generation and synaptic plasticity in IPSC derived neurons [35, 352, 
357, 358]. One potential strategy for enhancing neurite/axon outgrowth of 
transplanted cells is to dope or pretreat the CS-A hydrogel with BDNF or other 
axonal growth promoting molecules prior to transplantation. We found that BDNF 
levels were significantly elevated in the stroke core in CS-A+NPC treated mice 
(Figure 24), however, the levels of BDNF and the timing of BDNF enrichment may 
not have been sufficient to allow for axonal growth and penetration of the astrocytic 
barrier surrounding the stroke core. Another potential strategy for encouraging 
neuronal replacement via successful engraftment of transplanted cells is to 
stimulate the transplanted cells using optogenetic or chemogenetic methods. 
Unpublished work from the Wei/Yu lab has shown that stimulation of transplanted 
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cells can promote neurotrophic factor release and increase their expression of 
MAP2, TUJ1, Synapsin-1, which are axonal and synaptic markers, respectively.  
An alternative strategy to enhancing transplanted cell axonal growth is to 
reduce the glial barrier, which may permit axonal translation through the stroke 
core into the healthy tissue to form neuronal connections. We found that axons are 
indeed produced within the stroke core following transplantation (Figure 10). 
Outside of the stroke core where the astrocytic scar is not a concern, transplanted 
NPCs can differentiate into neurons and integrate into the host neuronal networks 
[17, 20, 56, 285]. This suggests that the glial scar may be the primary limitation to 
axonal and synaptic formation rather than the inherent potential of transplanted 
cells to integrate into the existing neural network. Numerous studies have 
discovered methods to reduce the glial barrier after stroke and other focal lesions 
such as spinal cord injury [349, 359, 360]. One notable technique that may be 
applicable to this study is the direct conversion of astrocytes into neuronal cells 
[361]. Ongoing work in the Wei/Yu lab has shown that viral infection of neuronal 
transcription factors into astrocytes after stroke can convert them into functional 
neurons. This strategy is especially attractive for the enhancement of cellular 
therapy directed to the stroke core since the effect of astrocyte direct conversion 
is two-fold: 1) the conversion of astrocytes into neurons may reduce the glial 
impediment to transplanted cells; and 2) additional neurons are formed in the place 
of what was previously the neuron-void astrocytic scar. One caveat to the 
approach of reducing the glial barrier is that over-reduction may be harmful. The 
glial scar, especially at the early stages of stroke, reduces progression of the stroke 
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core (see 3.3.4: The Inflammatory and Astrocytic Response to Cerebral Infarction). 
Some research suggests that at later time points, palisading astrocytes may even 
be necessary for successful axonal regeneration [116].  
 In summary, the current strategy of transplanted CS-A encapsulated NPCs 
into the stroke core is insufficient to promote functional recovery, however, there 
are multiple techniques and strategies which can be coupled with the versatile CS-
A hydrogel to potentially overcome these insufficiencies. In particular, methods to 
enable exogenous neuronal replacement and successful engraftment may 
synergize with CS-A encapsulated NPC transplantations. The potently angiogenic 
and arteriogenic effects of CS-A+NPC therapy are deserving of further study for 
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